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ABSTRACT 
   Skin is an essential biological barrier of the human body, and wound healing is the 
fundamental physiological process to keep its integrity. Chronic non-healing wounds are 
growing socioeconomic and health concerns, which longs for more understanding of their 
pathophysiology to discover effective treatments. In this thesis, we focused on how 
microRNAs (miR) work together with their target protein-coding genes to regulate the complex 
wound healing process, and by exploring the roles they play in chronic wounds we aimed to 
discover potential therapeutic targets.  
   In paper I, a distinct up-regulation of miR-31 in human acute wounds was identified from 
profiling analysis. We discovered miR-31 as a pivotal regulator in promoting keratinocyte 
proliferation and migration by targeting EMP1 during wound healing, emphasizing its 
importance in re-epithelialization. 
   In paper II, miR-34 family, as a famous tumour suppressor, popped out amidst the top 
upregulated microRNAs in venous ulcer. In vitro, miR-34a and miR-34c enhanced 
inflammatory response of epidermal keratinocytes via targeting LGR4 and positively regulating 
NF-κB signalling pathway. In vivo, mouse model of either miR-34 local overexpression or Lgr4 
knockout displayed impaired wound healing with excessive inflammation and suppressed cell 
growth. These suggest that miR-34 play a pathological role in chronic wounds by contributing 
to the excessive inflammation.  
   In paper III, in continuity with our previous report that miR-132 displays anti-inflammatory 
and pro-proliferative roles in keratinocytes, we studied the function of miR-132 in another 
major skin resident cell type fibroblasts. By both overexpression and inhibition, miR-132 was 
proved to facilitate migration of primary human dermal fibroblasts, through targeting RASA1 
and regulating Ras signalling. Since fibroblasts derived from chronic wounds are non-
migratory, our study suggests the miR-132-RASA1-Ras axis with potential therapeutic impact.  
   In paper IV, we tested the therapeutic potential of microRNAs, taken miR-132 as an 
example. A significant downregulation of miR-132 was revealed in diabetic foot ulcer. 
Intradermal injection of liposome-encapsulated miR-132 mimics effectively accelerated wound 
healing. Moreover, ex vivo human model exhibited ameliorated re-epithelialization upon miR-
132 topical application, denoting that local treatment of miR-132 deserves further evaluation 
in a clinical trial as a potential target for treating chronic wounds. 
   Conclusively, this thesis investigated the crucial functions of miR-31, miR-34 and miR-132 
in different phases of normal skin wound healing process and in chronic wounds, and pointed 
out a promising potential of microRNA-based therapy in treating chronic wounds. 
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1 BACKGROUND 
 
1.1 THE SKIN 
   Skin is the largest organ of the human body, serving as the first line of defense against the 
external environment. The skin not only serves as a physical and biochemical barrier against 
mechanical, chemical, radical injury and microorganisms, but also perform other functions such 
as sensory recognition, water protection and thermoregulation. 
   From the outside in, human skin is composed of three distinct anatomical compartments: 
epidermis, dermis, and hypodermis (Fig 1). In addition, skin contains cutaneous appendages 
including hair follicles, eccrine, apocrine and sebaceous glands and nails. 
 
Fig 1. Skin anatomy.  
 
1.1.1 Epidermis 
The epidermis of human skin is typically 0.05 - 0.1mm in thickness, consisting of stratified 
squamous epithelium that is devoid of blood supply. It continuously renews itself and constitutes 
different layers of cell (Fig 1). Stratum basale is the lowermost layer of epidermis formed by one 
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single layer of keratinocytes that majorly express keratin proteins 5 and 14. These cells remain 
attached to the basement membrane via hemidesmosomes at the interface of dermis and 
epidermis. Basal keratinocytes actively proliferate and differentiate while moving outwards to 
build spinous layer (stratum spinosum). Spinous keratinocytes primarily express keratin 1 and 
10, and remain connected by tight intercellular junctions called desmosomes. Further 
differentiation of suprabasal cells leads to formation of the next superficial layer of epidermis 
known as granular layer (stratum granulosum). In this layer, the cells become more flattened and 
elongated in appearance, have increased protein synthesis and lipogenesis, and express protein 
markers such as filaggrin, loricrin and involucrin. In the epidermis of the palms of the hands and 
soles of the feet, there is an additional layer called stratum lucidium located between the stratum 
granulosum and next outermost layer of stratum corneum. In stratum corneum, keratinocytes 
undergo terminal differentiation to form corneocytes or dead cells. These cells gradually loose 
their nuclei and organelles, secrete lamellar bodies, form cornified cell envelope, and eventually 
shed from the skin surface by process of desquamation (Blanpain and Fuchs, 2009, Fuchs, 
2016, J.A. McGrath, 2010, Menon, 2002). 
The cellular composition of epidermis mainly consists of > 90% keratinocytes. Additionally, it 
also contains other cell types (Fig 1) such as melanocytes, Merkel cells and immune cells 
including Langerhans’ cells and T cells. Melanocytes reside in the basal layer, and produce 
melanin which is transported to nearby keratinocytes to induce pigmentation and protect skin 
against UV radiation. Langerhans’ cells are antigen-presenting immune cells of the skin, with 
dendrites piercing through keratinocytes’ intercellular junctions to scout any penetrating 
antigens. The epidermis also hosts nerve-ending Merkel cells, which are essential for light-touch 
sensation and discrimination of shapes and texture (Di Meglio et al., 2011, J.A. McGrath, 2010). 
 
1.1.2 Dermis 
The dermis is separated from the epidermis by the basement membrane, which is majorly 
composed of collagen IV, VII and laminins. The dermis contains mainly extracellular matrix 
(ECM), e.g. collagens, elastic fibers and proteoglycans, providing essential structure, strength 
and elasticity to the skin. The dermis could be anatomically divided into the upper papillary 
dermis (stratum papillare) and the deeper reticular dermis (stratum reticulare), which are different 
in ECM composition: the papillary dermis is characterized by thin, poorly organized collagen fiber 
bundles which are primarily collagen I and III, in contrast to the thick, directionally oriented matrix 
networks in the reticular dermis (J.A. McGrath, 2010, Sorrell and Caplan, 2004). Dermal papillae 
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are the superficial ridge-like structures of the papillary dermis, which form the interactive surface 
between the epithelium and mesenchyme.  
Fibroblast is the major cell type synthesizing connective tissues in the dermis. Interestingly, 
fibroblasts present in papillary and reticular dermis have distinct gene expression profiles, such 
as for the genes related to the Wnt pathway, ECM components and immunoregulation, indicating 
they are a heterogeneous group of cells with different biological functions. For example, it has 
been known that papillary fibroblasts exhibit an anti-inflammatory phenotype, yet reticular 
fibroblasts are primed to respond to injury and infection. In the lower dermis, there are also 
preadipocytes, which are a subpopulation of fibroblasts with the capacity to differentiate into 
adipocytes (Lynch and Watt, 2018, Philippeos et al., 2018). 
In addition, the dermis comprises of a wide range of other cell types and structures such as 
sebaceous glands (e.g., sebocytes), blood vessels (e.g., endothelial cells, smooth muscle cells), 
eccrine and apocrine sweat glands, lymphatic vessels, as well as tissue-resident immune cells. 
As there are no blood and lymphoid vessels in the epidermis, those in the dermis are important 
in providing nourishment and clearing waste. The dermis also harbors neurons and nerve 
endings that mediate touch and heat (J.A. McGrath, 2010, Lynch and Watt, 2018). 
 
1.1.3 Hypodermis 
Hypodermis lies below dermis and is also called subcutaneous tissue. It is mainly composed 
of loose connective tissue and lobules of fat, accounting for approximately 80% of fat in human 
body (Lee et al., 2013). Subcutaneous fat tissue acts as padding cushion, energy reservoir and 
as thermo-regulator. The major cell types in hypodermis include adipocytes, pre-adipocytes, 
fibroblasts, macrophages and monocytes. In addition, adipose-derived stem cells stand for an 
abundant and accessible type of adult stem cells that can differentiate into multiple cell lineages 
and then further exert diverse influences (Mizuno, 2009). 
 
 
 
 12 
1.2 SKIN WOUND HEALING  
Wound healing is a fundamental and complex physiological process to keep the skin barrier 
intact. Wound healing is usually characterized as four sequential, albeit overlapping phases (Fig 
2), i.e.  hemostasis (0 – few hours after injury), inflammation phase (1 – 3 days), proliferation 
phase (4 – 21 days) and remodelling phase (21 days – 1 year).  
 
Fig 2. Simplified schematic representation of acute wound healing process: (A) Hemostasis and early 
inflammation phase. (B) Late inflammation phase and proliferation phase. (C) Remodelling phase. 
Reproduced and modified with permission from Foster et al., 2018. Copyright American Society for 
Clinical Investigation.  
 
1.2.1 Hemostasis phase 
Immediately following injury, the wound healing process initiates when platelets get exposed 
to ECM which triggers the coagulation cascade. A provisional clot (eschar), containing blood, 
fibrin, fibronectin and vitronectin, is formed within minutes to hours to rapidly stop bleeding and 
rapidly plug the defect (Reinke and Sorg, 2012). Simultaneously, the disrupted keratinocytes 
initiate release of pre-stored interleukin-1 (IL-1) as an early damage alert signal (Barrientos et 
al., 2008, Di Meglio et al., 2011). Activated platelets also produce a wide range of cytokines and 
growth factors, such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF) 
and transforming growth factor β (TGF-β) (Diegelmann and Evans, 2004). Together, cytokines 
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and chemokines play critical roles in the following healing process, for example CXCL1 (GRO-
α), CXCL5, CXCL8 (IL-8) are important chemoattractant for neutrophils; and CCL2, CCL3, 
CXCL10 attract monocytes/ macrophages. Therefore, the formation of provisional clot serves as 
a scaffold for the migration of these cells and keratinocytes (Reinke and Sorg, 2012). 
 
1.2.2 Inflammation phase 
In the early inflammatory phase, neutrophils are the primary cell type recruited to the wound 
site from the circulation. Stimulated by the chemokines released from the injured skin, blood 
vessel endothelial cells (EC) start to express adhesion molecules, e.g. vascular cell adhesion 
molecule (VCAM1), intercellular adhesion molecule 1 (ICAM1) and e-selectin (SELE), enhancing 
adhesion of neutrophils to the blood vessel wall and their extravasation. Once outside the 
circulation, neutrophils follow the gradient of chemokines and migrate to the injured area (Landen 
et al., 2016, Vestweber, 2015). Upon entering the wound, neutrophils exert phagocytosis to 
remove bacteria, foreign material and damaged tissue debris; secrete antimicrobial substances, 
protease and inflammatory cytokines, e.g. TNF-α, IL-1β, IL-6 (Eming et al., 2007, Reinke and 
Sorg, 2012). Neutrophils constitute nearly 50% of cells in the early stages of the wound 
(Ridiandries et al., 2018), and are normally present in the wound for 2-5 days unless infection 
occurs (Wilgus et al., 2013). 
In the late inflammatory phase, monocytes are recruited to the wound site from the circulation 
in response to CCL2, CCL3, and CCL5 secreted by neutrophils and later by themselves. 
Together with the skin-resident macrophages, they become the dominant inflammatory cell types 
in the wound for approximately two weeks post-injury (Ridiandries et al., 2018), and play an 
important role in shifting the inflammatory phase to the following proliferative phase, which is 
largely due to their impressive phenotype plasticity. Upon recognition of pathogen-associated 
molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs) and inflammatory 
signals (e.g. IFN-γ, TNF-α), macrophages polarize to a pro-inflammatory M1 phenotype (the 
classically activated macrophages), which produce cytokines and chemokines to attract more 
leukocytes, exert phagocytosis, promote Th1-Th17-type response and play host defense role 
(Snyder et al., 2016). Later on, M1 macrophages transit to the M2 phenotype (alternatively 
activated macrophages) with anti-inflammatory functions, which is key for inflammation 
resolution (Landen et al., 2016). M2 macrophages induce neutrophil apoptosis and ingest them 
(Meszaros et al., 1999, 2000), produce growth factors, e.g. vascular endothelial growth factor 
(VEGF) and TGF-β, to promote angiogenesis, re-epithelialization, fibroblast migration and matrix 
deposition (Landen et al., 2016, Snyder et al., 2016). 
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Other cell types that assist the process of inflammation include the resident mast cells, which 
release granules containing histamine, enzymes and other active amines, that can promote 
mononuclear cell leakage from surrounding blood vessels, wound fluid accumulation and 
inflammation signs, i.e., redness, heat, swelling and pain (Diegelmann and Evans, 2004). The 
adaptive immune system, including B and T cells, also involves in a later but more specific role, 
not only in the inflammation phase but subsequently in remodelling as well, which still needs 
more exploration (Landen et al., 2016). Moreover, dermal fibroblasts can also interact with these 
immune cells and regulate their infiltration, behavior and apoptosis by changing survival factors 
and chemokines gradient, to adjust inflammation levels (Landen et al., 2016, Smith et al., 1997). 
 
1.2.3 Proliferation phase 
Re-epithelialization initiates already in a few hours to one day post skin injury. The process 
is stimulated by nitric oxide (NO) and growth factors, such as EGF family (including EGF, TGF-
α, HB-EGF), keratinocyte growth factor (KGF), FGF, IGF-1 and nerve growth factor (NGF), 
produced by multiple cell types in the wound (Diegelmann and Evans, 2004, Martin, 1997). 
Wound-edge keratinocytes alter their gene expression profiles in order to invade through fibrin 
clot and migrate on granulation tissue towards the wound center, which forms a non-proliferative 
migrating leading edge (LE) (Aragona et al., 2017). In the proliferative hub surrounding the 
wound-edge, epidermal progenitors rapidly divide asymmetrically, while activated stem cells 
from interfollicular epidermis, hair follicle and infundibulum give rise to new progenitors that 
expand along LE to rebuild normal multi-cell-layered epidermis (Aragona et al., 2017, Lau et al., 
2009). 
During this phase, the provisional clot inserted in the wound bed is replaced by a newly-
formed granulation tissue. Activated by PDGF, bFGF and TGF-β, dermal fibroblasts in the wound 
neighbourhood and circulating fibrocytes (a group of bone marrow-derived mesenchymal 
progenitors) start to proliferate and migrate along the connective tissue matrix into the provisional 
clot (Martin, 1997, Mori et al., 2005). Around a week after wounding, fibroblasts fully invade into 
the fibrin clot, produce proteases, such as matrix metalloproteinases (MMPs), to degrade the 
provisional matrix while synthesizing new ECM. A portion of fibroblasts differentiate into 
myofibroblasts, expressing α smooth muscle actin (α-SMA) to establish a contractile force pulling 
the wound margins together (Martin, 1997).  
To supply the healing wound with oxygen and nutrients, it is important to form new blood 
vessels, i.e., neovascularization/ angiogenesis, which is induced by local hypoxia, low pH due to 
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high metabolic activity, growth factors (e.g. PDGF, bFGF, VEGF), hypoxia-inducible factor (HIF) 
and TGF-β in the wounds (Diegelmann and Evans, 2004, Martin, 1997). The activated ECs 
sprouted from the existing blood vessels (angiogenesis), and endothelial progenitors migrate 
towards the required site (vasculogenesis), proliferate and differentiate to form new capillaries, 
arteries and venules (Li et al., 2003, Reinke and Sorg, 2012). 
    
1.2.4 Remodelling phase 
The final stage of wound healing is the remodelling phase, also called the maturation phase, 
which lasts for months to years depending on the size and type of the wound. At the end of the 
proliferation phase, angiogenesis and proliferation cease. The provisional matrix (mainly fibrin, 
fibronectin, proteoglycans and collagen III) are gradually degraded by MMPs; meanwhile more 
collagen I is being produced by the residual fibroblasts to reconstruct a tough scar tissue with 
tensile strength comparable (maximum 80%) to the unwounded skin (Demidova-Rice et al., 
2012). Excessive cells either leave the wound or are subjected to apoptosis, such as recruited 
immune cells and myofibroblasts. Nerve regeneration progresses. The number and flow of new 
blood vessels diminish and regress when healing is complete (Reinke and Sorg, 2012). In most 
cases, although wounds get repaired, appendages fail to regenerate once lost.  
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1.3 CHRONIC WOUNDS 
Chronic wounds, or hard-to-heal wounds, are defined as cutaneous wounds failing to heal 
within 6 weeks (Tricco et al., 2015). They are cutaneous defects which fail to proceed through 
an orderly and timely tissue repair to retrieve complete structure and integral function (Eming et 
al., 2014). The major causes underlying chronic wounds are vascular insufficiency 
(venous/arterial ulcer, VU/AU), diabetes mellitus (diabetic ulcer, DU) and local mechanical 
pressure (pressure ulcer, PU). More than 90% of chronic wounds are categorized as VU, DU or 
PU (Mustoe et al., 2006). Systemic factors, e.g. advanced age, malnutrition and compromised 
immune status, also sow the seeds for impaired healing (Eming et al., 2014). Chronic wounds 
result in a heavy health care burden, growing socioeconomic loss, and decreased patients’ 
quality of life, high amputation rate and even mortality. It has been estimated in developed 
countries, approximately 1-2% of populations will experience hard-to-heal wound (Gottrup, 
2004), which already consumes 2-4% of their health care budget in developed countries 
(Frykberg and Banks, 2015, Gottrup et al., 2001, Richmond et al., 2013). 
 
Fig 3. Illustrations of molecular and cellular mechanisms that are impaired in chronic wounds. 
Reproduced with permission from Eming et al., 2014. Copy Right American Association for the 
Advancement of Science 
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1.3.1 Venous ulcer and diabetic ulcer 
VU constitutes ~80% of all non-healing leg ulcers (Medina et al., 2005), with a rising incidence 
up to 3 to 4% among the elderly (Eming et al., 2014), due to various reasons that lead to venous 
hypertension and chronic venous insufficiency. VUs are clinically characterized as superficial 
painless cutaneous defects with fibrous granulation tissue and cloudy proteolytic exudates 
mostly on lower extremities, where the whole limb may exhibits edema, surrounding varicose 
veins, eczema and hemosiderin hyperpigmentation (Medina et al., 2005, Valencia et al., 2001).  
Edema plays a major role in VU, which causes lower tissue oxygen level (Mustoe et al., 2006). 
Fibrotic cuffs wrapping capillaries also contribute to the pathogenesis by interfering with oxygen 
and nutrition exchange, inducing endothelial damage, lipodermatosclerosis, and entrapping 
leukocytes (Browse and Burnand, 1982, Valencia et al., 2001).  
Diabetes is an escalating global burden, with 422 million diabetic patients worldwide 
(Organization, 2016). Up to 20% of them suffer from impaired wound healing, and the most 
common form is diabetic foot ulcer (DFU) (Guo and Dipietro, 2010). Among all kinds of chronic 
wounds, DFU is the most notorious one – most difficult to heal even after multiple treatments 
(Amin and Doupis, 2016), which accounts for >80% lower leg amputations (Frykberg and Banks, 
2015). DFUs are often located on more distal extremities like calf and feet, with necrotic base 
and irregular margins (Medina et al., 2005). Under diabetes milieu, prolonged exposure to 
hyperglycemia leads to increased glycation of proteins and accumulated glycation end products 
(AGEs), which disturb numerous cellular responses, such as suppressing bFGF, EGFR 
signalling (Medina et al., 2005). Upon injuries, diabetic patients exhibit reduced capacity of 
recruiting immune cells, which leads to delayed inflammatory response, increasing the risk of 
infection (Medina et al., 2005). Pathological macrovascular and microvascular changes and 
peripheral neuropathy in diabetic patients are important pathogenetic risk factors for 
development of DFU (Amin and Doupis, 2016, Cavanagh et al., 2005).  
 
1.3.2 Pathophysiology of chronic wounds 
Chronic wound abnormalities are commonly featured as persistent inflammation, presence 
of infection and biofilm, hyper-proliferative but non-migratory keratinocytes, senescent 
fibroblasts, impaired angiogenesis, excessive proteolytic enzymes and reactive oxygen species 
(ROS) (Fig 3) (Diegelmann and Evans, 2004, Eming et al., 2014, Martin and Nunan, 2015).  
Nevertheless, the molecular mechanisms behind the impairment of wound healing are still poorly 
understood. This may be partially due to the complexity of the normal wound healing process, 
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difficulty capture early pathophysiological events and lack of animal models recapitulating non-
healing wounds. Future investigations are required to reveal the complicated and dynamically 
changing microenvironment of chronic wounds, and there might be sharing pathological 
mechanisms between different etiologies and as well unique factors/ pathways influencing 
individual subtypes of chronic wounds. 
 
1.3.2.1 Hypoxia, ischemia and reperfusion 
Most chronic wounds (VU, AU, DU) are associated with peripheral vascular diseases (PVD) 
with insufficient delivery of oxygen and nutrients. Local pressure-induced ischemia is also 
implicated in development of PU (Sen, 2009). Additionally, hypoxia is intensified by increased 
energy consumption during healing, ROS, infection, pain and anxiety etc (Sen, 2009). Ischemia-
reperfusion occurs repetitively, leading to cytotoxic tissue damage, for instance, damage of 
mitochondria oxidative function, cell swelling, leukocytes trapping, overproduced ROS, and 
microvascular dysfunction (Mustoe et al., 2006). Insufficient capillary growth has been observed 
in both DU and VU (Eming et al., 2014), which further exacerbates the hypoxic situation in 
chronic wounds.  
 
1.3.2.2 Microbiome and infection 
Bacteria exist in all open wounds, but are normally limited to contamination or colonization, 
sometimes local infection, but rarely develop into spreading infection (cellulitis or even 
septicemia) (Edwards and Harding, 2004). Polymicrobial presence has been studied in chronic 
wounds and the bioburden, including the microbial diversity, microbial load, and the presence of 
pathogenic microorganisms, has been reported to play a pivotal role in impaired wound healing 
even without clinical infection (Misic et al., 2014). The most prevalent bacteria present in chronic 
wound are Staphylococcus, Pseudomonas, and Corynebacterium. In chronic wounds, bacteria 
often aggregate in a self-secreted extracellular polysaccharide biofilm, which protects them from 
host immune response or treatment with antibiotics (Zhao et al., 2013). Bacterial products and 
antibacterial immune reactions damage tissue and even lead to necrosis (Landen et al., 2016). 
Failure to clear these foreign bodies and the sustained presence of high bacterial load result in 
a sustained influx of pro-inflammatory cells and increased inflammation (Eming et al., 2014).  
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1.3.2.3 Persistent inflammation 
In chronic wounds, the orderly efficient healing process is disturbed, and wounds are stuck 
in a chronic inflammatory state (Eming et al., 2009). Comparing the exudate from chronic wounds 
with healthy wounds, the level of mediators characterizes for persistent inflammation, such as 
cytokines and S100 family members, were found to be elevated (Beidler et al., 2009, Eming et 
al., 2010). The excessive cellular infiltration involving neutrophils, pro-inflammatory M1 
macrophages and prolonged presence of T cells with low CD4+/CD8+ ratio further strengthens 
this observation (Loots et al., 1998). These cells produce proteases degrading ECM, growth 
factors, clotting factors, complements and immunoglobulin, and also release free oxygen 
radicals further damaging tissue (Dovi et al., 2004). Impairment of neutrophils phagocytosis by 
macrophages has been observed in DFU, which prolongs inflammation and delays healing 
(Khanna et al., 2010). Moreover, defection of M1 to M2 macrophage phenotype transition has 
been implied in the pathogenesis of chronic wounds, as M2 macrophages are important to 
remove neutrophils, resolve inflammation and initiate the following proliferative phase (Landen 
et al., 2016).  
 
1.3.2.4 Ageing and senescence 
Advanced age is an obvious common feature that most chronic wounds patients share, 
regardless of their diverse etiologies. Changes of hormones with ageing, particularly estrogens 
and androgens, are principle contributing factors in compromised wound healing despite of 
chronological ageing (Eming et al., 2014, Wilkinson and Hardman, 2017). Reduced number and 
function of stem cells/ progenitors, as well as irreversible cell aging with limited proliferative 
potential and altered response to stress also make the elderly prone to the development of 
chronic wounds(Makrantonaki et al., 2017). Moreover, cells at wound site enter into a replicative 
premature senescence due to constant exposure to inflammation and stress (Mustoe et al., 
2006). This leads to a senesce-associated secretory phenotype which alter the 
microenvironment and impact neighbouring cells (Makrantonaki et al., 2017). For example, 
prematurely aged fibroblasts have diminished migratory capacity and are unresponsive to growth 
factors. They secret proteolytic MMPs, which inhibit proliferation, angiogenesis, and induce 
uncontrolled tissue degradation (Jun and Lau, 2010, Martin and Nunan, 2015, Medina et al., 
2005). Senescent keratinocytes also produce anti-angiogenic factor maspin, impairing wound 
healing (Nickoloff et al., 2004).  
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1.3.2.5 Other pathological factors 
   In the wound-edge of skin ulcers, hyper-proliferative keratinocytes demand frequent cycling of 
epidermal progenitor/ stem cells, which could cause fast reduction or even depletion of local 
stem cell populations (Eming et al., 2014). A variety of other risk factors were also reported to 
linked to impaired wound healing, for instance, obesity, stress, alcoholism, smoking, disease 
such as jaundice and uremia, and medications such as glucocorticoid steroids and 
chemotherapy (Guo and Dipietro, 2010, Jozic et al., 2017).  
 
1.3.3 Current treatments for chronic wounds 
Conventional treatments for chronic wounds include non-specific and specific interventions. 
Thorough assessment of vascular state, drug usage, patients’ general health and nutrition status 
is fundamental for design of suitable treatment strategies. Wound bed preparation and extensive 
surgical debridement are used to remove exudate debris and devitalized wound-edge tissues to 
achieve a well-vascularized bed (Pang et al., 2017) in order to initiate secondary healing (Tsourdi 
et al., 2013). It is critical to eliminate infection with antiseptics and antibiotics, based on the results 
of pathogen identification (Cavanagh et al., 2005, O’Toole, 2010, Valencia et al., 2001). It is 
imperative to minimize skin irritation or friction and protect wounds from further contaminations 
and maintain proper moisture and temperature conditions. To implement this, different types of 
wound dressings have been developed, such as semipermeable films, hydrogels, cellulose and 
collagens etc.  (Jones et al., 2018, O’Toole, 2010, Pang et al., 2017). Moreover, various kinds of 
skin grafting, e.g. allogenic or autologous skin flap, tissue-engineered skin equivalents, are 
commonly used to ease the pain and assist in healing process. However, their associated 
limitations in form of reduced vascularization, poor mechanical integrity and immune rejection 
impedes their extensive clinical utility (O’Toole, 2010, Stone et al., 2017, Tsourdi et al., 2013). 
Specific assessments and treatments are crucial in targeting primary etiology. For example, 
compression therapy is routinely used for VU to reverse edema. This is a cornerstone and 
demonstrates the largest effect on successful healing rate in most VU treatment (Valencia et al., 
2001). VU and AU benefit from laser treatment and blood vessel surgery, which addresses 
circulation problem with less recurrence. For DU, metabolic and glycemic control as well as 
offloading are helpful, and surgical interventions in use include tenotomy, tendon lengthening, 
reconstruction, or removal of bony prominences, which may cause secondary ulceration 
(Cavanagh et al., 2005). 
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1.3.4 Progress of chronic wound research 
   The efforts aiming to cure chronic wounds are on-going. Local delivery of growth factors, 
including bFGF, GM-CSF, EGF, and KGF-1, has not achieved satisfying outcomes in clinical 
trials; only rhPDGF-BB entered clinical use but with limited effects (Barrientos et al., 2014, 
Barrientos et al., 2008, Makrantonaki et al., 2017, Pang et al., 2017). This may be due to the 
reduced expression or responsiveness of growth factor receptors on the wound-edge cells and 
rapid degradation of these growth factors in the proteolytic wound environment (Barrientos et al., 
2008, Pang et al., 2017).  
In recent years, a myriad of advanced nanotechnologies have been developed for targeting 
specific problems of non-healing wounds. Various nanoparticle, polymer, lipid and peptide based 
therapeutic intervention strategies are being designed to address the problems associated with 
chronic wounds, such as nanomaterials with intrinsic beneficial properties for wound healing, or 
delivery vehicles/ scaffolds for other therapeutic agents. However, a series of challenges 
surround nanoparticle-based therapeutics due to their elusive physicochemical properties, 
biological behaviours, immune toxicity and difficulty in purification (Hamdan et al., 2017). 
Therapies with live cells, e.g., keratinocytes, fibroblasts, platelets and bioengineered skin 
equivalent, have been used in clinical practice, which exhibit promising effects in some VU and 
DU cases (Brem et al., 2003, Falanga et al., 1998, Stone et al., 2017, You and Han, 2014), which 
still needs to be tested and validated. Continuous  efforts have been made for the development 
of stem cell-based treatments by using, e.g., mesenchymal stem cells (MSC) (Cao et al., 2017), 
bone marrow-derived stem cells (BMSC), adipose-derived stem cells (ADSC), epidermal stem 
cells (ESC) and induced pluripotent stem cells (iPSC), which have shown promising results in 
animal wound models but with limited success in clinical trials (Duscher et al., 2016, Pang et al., 
2017). Stem cell-based treatments face problems, such as low stem cell yield, high cost, poor 
cell delivery and survival, and impaired in vivo cellular function (Duscher et al., 2016).  
Recently, use of commensals or engineered microorganisms provides an alternative 
therapeutic approach towards non-healing wounds. Commensal bacteria could compete with 
pathogenic bacteria, produce antimicrobial substances, inactivate toxins/ metabolites, and 
modulate host immune response. In vivo and in vitro studies have demonstrated that topical 
application of specific strains or certain bacteria extracts, such as S. epidermis, lactobacilli and 
bifidobacteria, may improve wound healing. However, further research is required to learn more 
about the underlying mechanisms involving gut–brain–skin axis and probiotic–host interactions, 
and to explore their effects in patients with complicated background (Lukic et al., 2017).  
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The complicated landscape of chronic wounds represents a major obstacle in finding new 
efficient therapies.  Overall, these current capabilities are economically demanding and require 
special expertise to implement and achieve benefits in chronic wound treatment modalities. 
Moreover, efficient knowledge of molecular pathology of chronic wounds can help us in better 
designing of advanced technologies with the potential to get clinically translated.  
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1.4 MICRORNAS 
As stated in the central dogma of molecular biology, genomic DNA is transcribed to RNA, 
and RNA is translated into protein. However, the Encyclopedia of DNA Elements (ENCODE) 
and Functional ANnoTation Of the Mammalian genome (FANTOM) projects have revealed that 
only ~2% of our DNA encode protein, ~97 – 98% of transcription results in non-protein-coding 
RNAs (Esteller, 2011). Many of these non-protein-coding RNAs have been shown to play 
important regulatory roles in the cells. This thesis focuses on one group of short non-coding 
RNAs, i.e. microRNAs.  
 
1.4.1 MicroRNA biogenesis 
MiRNAs are single-stranded non-protein coding RNA with around 22 nucleotides on average 
(19 – 25 nt), which are highly conserved post-transcriptional gene regulators (Bartel, 2004). Most 
miRNA genes are transcribed by RNA polymerase II to form primary precursors (pri-miRNAs), 
which are subjected to the cleavage by nuclear RNase III Drosha-DGCR8 to shorter hairpin-
shaped precursors (pre-miRNAs, approximately 60 nt) and exported from the nucleus to the 
cytoplasm (Ameres and Zamore, 2013). An alternative pathway was reported that some intronic 
microRNA precursors can be processed by RNA splicing bypassing the cleavage of Drosha 
(Ruby et al., 2007). In the cytoplasm, pre-miRNAs are further processed into short RNA duplexes 
(miRNA:miRNA*) by another RNase III enzyme DICER, and then separated into single strands 
to form mature miRNAs (Bartel, 2004, Ha and Kim, 2014) (Fig 4). Some miRNAs are transcribed 
from their own transcription unit with independent promoters. About 40% miRNAs are derived 
from the introns and 10% from the exons of other coding or non-coding transcripts, sharing 
transcriptional regulation with the host genes (Monteys et al., 2010, Ozsolak et al., 2008). MiRNA 
genes are often clustered together in the genome, which are transcribed as a multi-cistronic 
primary transcript and then further processed; even though, the expression pattern of these 
miRNAs may differ within the cluster due to complicated post-transcriptional regulation (Bartel, 
2004, Ha and Kim, 2014, Zhao and Srivastava, 2007).  
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Fig 4. Illustration of microRNA biogenesis. Reproduced with permission from Ameres et al., 2013. 
Copyright Springer Nature. 
 
1.4.2 The action modes of microRNAs 
To mediate their biological function, mature miRNAs are loaded to the argonaute (AGO) 
protein to form the RNA-induced silencing complex (RISC), and bring this enzyme complex to 
the target messenger RNA (mRNA) (Ameres and Zamore, 2013). The targeting process is 
mainly mediated by the pairing between the miRNA seed region (the 2nd-7th nucleotides from the 
5’ end of a miRNA) and the miRNA binding sites (MBS) at the 3’ untranslated region (UTR) of 
target mRNAs. Additionally, the supplementary/compensatory base-pairing between the rest 
part of a miRNA and the MBS is responsible for defining the specificity and efficiency of miRNA-
mediated regulation (Bartel, 2009, Jonas and Izaurralde, 2015). As a result, miRNAs down-
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regulate the expression of target genes by repressing translation, reducing stability or degrading 
their mRNAs. Moreover, the RISC can also silence target gene at the genomic level by formation 
of heterochromatin or via DNA elimination (Pratt and MacRae, 2009). A single miRNA usually 
has dozens and even hundreds of targets, which often form a signalling network, exerting the 
biological functions of this miRNA by fine-tuning the protein-coding genes (Bartel, 2009). 
MiRNAs have been demonstrated to play important roles in almost all the biological and 
physiological processes investigated to date. In line with this, aberrant miRNA expression and 
function have been identified in many diseases. Therefore, modulation of these disease-related 
miRNAs has been shown to be beneficial in several clinical trials, thus making microRNA a 
favourable candidate to be explored for novel therapy (van Rooij and Kauppinen, 2014).  
 
1.4.3 MicroRNAs in the skin 
MiRNAs have been identified as important regulators in the skin (Mancini et al., 2014, 
Mannucci et al., 2017, Schneider, 2012). Using mice models with skin-specific knock-out of Dicer 
or Dgcr8, miRNAs have been shown to be essential for epidermal and hair-follicle development, 
maintenance and function (Andl et al., 2006, Yi et al., 2006, Yi et al., 2009). Several miRNAs are 
highly expressed in the skin, suggesting their potential functional roles in skin morphogenesis 
(Yi et al., 2006). For example, miR-203 as a skin-specific miRNA promotes keratinocyte 
differentiation and restricts cell proliferation, and it defines a molecular boundary between 
proliferative basal progenitors and differentiating suprabasal cells (Sonkoly et al., 2007, Sonkoly 
et al., 2010b, Yi et al., 2008). Inhibition of miR-34a and miR-34c restores keratinocyte cell cycle 
progression (Antonini et al., 2010). Among the highest expressed miRNA in skin stem cells, miR-
125b serves as a repressor of stem cell differentiation (Zhang, 2011), and miR-205 controls 
neonatal expansion of stem cells and is indispensable for postnatal epidermal homeostasis (Teta 
et al., 2012, Wang et al., 2013). In terms of dermal homoeostasis, miR-145 is highly expressed 
in fibroblasts, and its inhibition enhances reprogramming of dermal fibroblasts to induced 
pluripotent stem cells (Barta et al., 2016).  
The roles of microRNAs have also been studied in different skin disorders. Our colleagues 
were the first to demonstrate differentially expressed miRNAs in psoriasis (Sonkoly et al., 2007), 
and further studied the functions of the top regulated ones. For instance, higher expression of 
miR-21 in psoriasis may contribute to skin inflammation by inhibiting T cell apoptosis (Meisgen 
et al., 2012). Up-regulation of miR-31 in psoriasis contributes to skin inflammation by regulating 
communication between immune cells and keratinocytes (Xu et al., 2013). Also up-regulated in 
psoriasis, miR-146a suppresses TLR2-induced as well as IL-17-mediated inflammatory 
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responses in keratinocytes (Meisgen et al., 2014, Srivastava et al., 2017). In atopic dermatitis, 
miR-155 is overexpressed and increases T-cell proliferative responses (Sonkoly et al., 2010a). 
In skin cancer, miR-125b is top down-regulated in cutaneous squamous cell carcinoma (cSCC) 
and functions as a tumour suppressor (Xu et al., 2012). Whereas miR-31 is overexpressed in 
cSCC and enhances tumour cell motility and colony formation ability. (Wang A. et al., 2014). 
MiR-203 acts as a tumour suppressor in both cSCC and melanoma (Lohcharoenkal et al., 2018, 
Lohcharoenkal et al., 2016). 
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1.5 MICRORNAS IN SKIN WOUND HEALING 
Emerging studies have shown that miRNAs play key roles in all phases of normal skin wound 
healing and also involved in the pathogenesis of chronic wounds (Herter and Landen, 2017, Li 
and Landen, 2017).  
 
1.5.1 MiRNAs in normal skin wound healing 
1.5.1.1 Inflammation phase 
Several miRNAs have been found to regulate wound inflammation. For instance, miR-146a 
functions as a negative regulator of inflammatory response in keratinocytes and macrophages 
(Hou et al., 2009, Srivastava et al., 2017, Taganov et al., 2006, Xu, 2012). Its expression is 
upregulated by activation of Toll-like receptors (TLR2-5) (Taganov et al., 2006). As a negative 
feedback loop, miR-146a inhibits TLR-2-induced inflammation by targeting several key factors 
within the NF-κB signalling pathway such as IL-1 receptor-associated kinases 1 (IRAK1), IRAK2, 
and tumour necrosis factor receptor-associated factor 6 (TRAF6) (Meisgen et al., 2014). The 
level of miR-146a was found decreased in the inflammation phase of human skin wound healing 
(Li et al., 2015) and also in the wound of diabetic mice with increased NF-κB signalling (Xu, 
2012).  
A mouse model lacking miR-155 expression exhibits reduced inflammatory cells recruitment 
and faster healing with improved regenerated architecture (van Solingen et al., 2014, Yang et 
al., 2014). In a rat model, miR-155 inhibition shows faster healing of acute wounds, with reduced 
inflammation (Ye et al., 2017). MiR-23b has recently been shown to promote cutaneous wound 
healing in vivo via inhibition of the inflammatory responses (Li, 2018). MiR-21 has been studied 
in multiple aspects regarding inflammation in wounds. MiR-21 has been identified as an 
important regulator for resolving inflammation in wounds, which inhibits LPS-induced 
inflammatory response and increases IL-10 production in macrophages (Das et al., 2014, 
Recchiuti et al., 2011). In another study, it has been shown that overexpression of miR-21 in 
wounded rat model significantly improves the healing rate owing to activation of AKT/PI3K 
signalling pathway by targeting PTEN. (Han et al., 2017).  
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1.5.1.2 Proliferation phase 
Besides its anti-inflammatory role, miR-21 also facilitates migration of keratinocytes and 
fibroblasts (Madhyastha et al., 2012, Yang et al., 2011), and promotes proliferation and 
fibrogenesis of fibroblasts from hypertrophic scars or keloid (Li et al., 2016, Liu et al., 2014, Zhu 
et al., 2014). Interestingly, both inhibition (Wang et al., 2012, Yang et al., 2011) and 
overexpression (Pastar et al., 2012) of miR-21 delayed wound healing in vivo by impairing re-
epithelialization and granulation tissue formation. A parallel study have shown that miR-21 KO 
mice exhibits decreased healing rate possibly due to the targeting of Smad7-Smad2/3-Elastin 
pathway (Li et al., 2018). Additionally, knock-in or intradermal injection of miR-21 in aged mice 
significantly benefits wound healing by improving age-associated skin wound defects (Long et 
al., 2018).  
There’re several microRNAs reported as multiple players involved in diverse cellular functions. 
MiR-130a delays re-epithelialization in human ex vivo skin wound model by targeting early 
growth response factor 3 (EGR3) and leptin receptor (LepR) in primary human keratinocytes 
(Pastar et al., 2012). It also promotes angiogenesis by targeting mesenchyme homeobox 2 
(MEOX2) and homeobox A5 (HOXA5) in endothelial cells (Chen and Gorski, 2008). MiR-210 
expression is induced by hypoxia through stabilizing HIF-1α, which results in downregulation of 
the cell-cycle regulatory protein E2F3 in keratinocytes and impairs re-epithelialization (Biswas et 
al., 2010). Hypoxia-induced miR-210 also promotes angiogenesis by inhibiting the receptor 
tyrosine kinase ligand Ephrin-A3 (Fasanaro et al., 2008). Moreover, as an “ischemic memory”, 
increased miR-210 expression attenuates keratinocytes proliferation. Accordingly, local 
inhibition of miR-210 improved ischemic wound closure (Ghatak et al., 2016). In another 
independent study, miR-219-5p is also induced by hypoxia in keratinocytes, and its target 
TMEM98 could inhibit inflammatory response while enhance cell proliferation and migration 
(Tang and Ran, 2018). In addition to its anti-inflammatory role, local overexpression of miR-155 
accelerates in vivo wound healing by targeting MMP2 to promote keratinocytes migration (Yang 
et al., 2017). 
For re-epithelialization specifically, miR-17-3p promotes keratinocyte proliferation and 
migration (Yan et al., 2017). An acute upregulation of miR-200c were reported at the early phase 
of wound healing in aged skin, and miR-200c inhibits keratinocyte migration and delays re-
epithelialization of human ex vivo wounds (Aunin et al., 2017). MiR-203 shows a strong 
expression in the hyperplastic suprabasal epidermis surrounding the wound but is almost 
completely absent in the migratory front, and in terms of function miR-203 inhibits keratinocytes 
proliferation and migration, contributing to re-epithelialization (Deppe et al., 2016, Viticchie et al., 
2012).  
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As for angiogenesis, overexpression of miR-148b promotes endothelial cell migration, 
proliferation and angiogenesis by targeting TGFB2 and SMAD2 (Miscianinov et al., 2018). Down-
regulation of miR-200b by hypoxia was reported in endothelial cells, which induces angiogenesis 
to accelerate wound healing by targeting ETS-1, GATA2 and VEGFR2 (Chan et al., 2011, Chan 
et al., 2012). A synthetic inhibitor of microRNA-92a positively regulates angiogenesis and wound 
healing in both db/db mice and normal pigs (Gallant-Behm et al., 2018). Furthermore, inhibition 
of miR-92a improves wound healing in diabetic mice by targeting Itga5 and Sirt1 to enhance cell 
growth and angiogenesis (Lucas et al., 2017). 
 
1.5.1.3 Remodelling phase 
MiR-29 family is important regulator in fibroblasts of multiple organs associated with TGF-β1-
directed fibrogenesis (Cushing et al., 2011, Jafarinejad-Farsangi et al., 2015, Maurer et al., 2010, 
van Rooij et al., 2008, Yang et al., 2013). In a previous report, in vivo local delivery of miR-29b 
improves wound remodelling as depicted by reduced contraction, increased collagen III/I 
ratios(Guo et al., 2018, Monaghan et al., 2014), and reduces excessive scar formation owing to 
suppression of TGF-β1-Smad-CTGF signalling pathway (Guo et al., 2017). MiR-98 has been 
proved to directly target Col1α1 gene, leading to declined viability and increased apoptosis of 
fibroblasts (Bi et al., 2017). MiR-185 also play as an inhibitor of fibroblast growth, through directly 
targeting TGF-β1 and Col-1 genes (Xiao et al., 2017). In a rat wound healing model, miR‑149 
ameliorates arrangement of collagen bundles and attenuates inflammatory cell infiltration (Lang 
et al., 2017). MiR-203 increases epidermal stem cell differentiation to myofibroblasts by targeting 
Hes1, and inhibition of miR-203 accelerates wound closure and reduces scar formation 
accompanied with increased collagen reassignment (Zhou et al., 2018). In addition, miR-1908 
has been found to increase fibroblast proliferation and production of TGF-β1, IL-1α, TNF-α and 
type I collagen, and miR-1908 inhibitor reduces scar formation in burn wounds(Xie et al., 2016).  
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Fig 5. Schematic illustration to demonstrate our research outline. 
 
1.5.2 MiRNAs in chronic wounds 
Aberrant expression and function of several miRNAs have been reported in chronic wounds. 
In mouse diabetic model, miR-26a is found upregulated in the wounds compared with wild-type 
mice, and inhibition of miR-26a accelerated wound closure by inducing angiogenesis and 
increasing granulation tissue formation (Icli et al., 2016). Increased expression of miR-15b in 
diabetic mouse wounds is associated with impaired angiogenic response (Xu et al., 2014). MiR-
27b rescues impaired the functions of bone marrow-derived angiogenic cells and improves 
wound healing (Wang J. M. et al., 2014). TNF-α neutralization leads to miR-200b 
downregulation, which supports wound closure by improving angiogenesis in diabetic mice 
(Chan et al., 2012).  
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A study comparing the plasma miRNA profile in type 2 diabetic (T2DM) patients with and 
without chronic wounds identified 41 deregulated miRNAs, among which decreased miR-191 
and miR-200b levels were validated. Furthermore, the authors showed that miR-191 secreted 
by endothelial cells or platelets was either taken up by dermal endothelial cells to reduce 
angiogenesis, or taken by fibroblasts to inhibit migration, thereby causing delay in wound repair 
(Dangwal et al., 2015).  In another study it was shown that hematopoietic stem cells of diabetic 
mice differentiate less into macrophages, where decreased let-7d-3p directly upregulates 
Dnmt1, leading to impaired wound healing (Yan et al., 2018). A recent study reported miR-129 
and miR-335, which are significantly downregulated in the serum and skin tissues of diabetic 
patients, and are known to improve diabetic wound healing by targeting Sp1 to repress MMP9 
expression (Wang et al., 2018).  
MiR-146a has been found decreased in diabetic mouse wounds (Xu, 2012), and application 
of miR-146a conjugated with cerium oxide nanoparticles improved wound healing of diabetic 
mice without impairing biomechanical properties of the healed skin (Zgheib et al., 2018).  
Additionally, miR-296-5p is also found significantly decreased in amputated lower limb tissues 
of diabetic patients compared with the adjacent normal tissue, and overexpression of miR-296-
5p inhibits β-cells proliferation by targeting sodium-glucose transporter 2 and increases the 
healing rate of diabetic wounds both in vivo and in vitro (Liu X. et al., 2018). In primary fibroblast 
derived from diabetic foot ulcers in comparison to nondiabetic foot fibroblasts, integrative 
analysis of miRNA and mRNA paired expression profiling reveals inhibition of cell growth and 
motility, as well as enhancement of cell differentiation and senescence, where induced miR-21-
5p, miR-34a-5p and miR-145-5p play important roles (Liang et al., 2016).  
In a porcine biofilm-infected wound model, miR-146a and miR-106b are induced by biofilm at 
wound-edge, which impairs epidermal barrier function (Roy et al., 2014). Experiments with miR-
142-/- mice indicates that miR-142 family is indispensable for the clearance of S. aureus from 
wound sites to prevent infection (Tanaka et al., 2017). In S. aureus-infected wild-type mice 
wounds, treatment with miR-223 KO neutrophils or anti-miR-223 markedly rescues the healing 
process from the  chronic, slow healing wounds, with prolonged neutrophil activation and 
enhanced clearance of bacteria (de Kerckhove et al., 2018). S. aureus, the prevalent pathogen 
in DFUs, were found to induce miR-15b-5p expression in both acute wounds and DFUs, and 
miR-15b-5p represses DNA repair and inflammatory response (Ramirez et al., 2018).  
Negative-pressure wound therapy (NPWT) is one of the mostly used and effective methods in 
treating chronic wounds, where miR-195 is revealed markedly upregulated 7 days after NPWT 
together with increased microvessel density in granulation tissue (Liu Y. et al., 2018).  
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MiR-29a expression is suppressed in DFU, but treatment of mesenchymal stem cells (MSCs) 
has been shown to improve diabetic wound healing via increasing miR-29b expression which in 
turn leads to decreased expression of MMP9, thereby improving collagen I content in diabetic 
wounds (Xu et al., 2017). Bone marrow-derived mesenchymal stem cells (BM-MSC) treated 
diabetic mice wounds exhibit lower miR-155 expression and faster wound healing (Jiang L., 
2016). Another report suggested that molecular modification of MSCs by inhibiting miR-205 
improves their therapeutic effects on diabetic wounds by relieving its target VEGF expression 
(Zhu et al., 2017). 
Together, these studies indicate that miRNAs play important roles in the pathophysiology of 
chronic wounds, which makes them promising therapeutic and diagnostic entities. 
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2 AIMS 
 
   In this thesis, we aimed to explore the roles of several important microRNAs and the gene 
networks regulated by them in the human skin wound healing process and in chronic non-healing 
wounds.  
   The objectives of this research were 
 To understand the expression and function of miR-31 in epidermal keratinocytes during 
normal skin wound healing (paper I);  
 To determine the functional role of miR-34 family in keratinocytes of normal wounds and 
in venous ulcers (paper II); 
 To identify the function of miR-132 in dermal fibroblasts during skin wound healing (paper 
III); 
 To explore the therapeutic potential of miR-132 in diabetic ulcers (paper IV). 
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3 MATERIALS AND METHODS 
 
Patients and healthy donors 
   In this study, patients with non-healing ulcers, including venous ulcer patients (VU) and 
diabetic foot ulcer patients (DFU), that persisted for more than 6 weeks were enrolled. Exclusion 
criteria were apparent soft tissue infection in need of systemic antibiotics, under systemic 
antibiotics 24 hours prior to biopsy, as well as immune-compromised patients. Tissue samples 
were taken using a 4-mm biopsy punch at the non-healing edges of chronic wounds (Fig 6A). In 
addition, we recruited healthy donors who have no diabetes, skin disease, unstable heart 
disease, infections, bleeding disorder, immune suppression, and any on-going medical 
treatments. We created full-thickness excisional wounds using a 4-mm biopsy punch on the skin 
of each healthy donor, and the excised skin was saved as an intact skin control. The wound-
edge tissue was collected using a 6-mm biopsy punch one and / or seven days later (Fig 6B). 
Local lidocaine injection was used for anaesthesia while sampling. All donors have signed a 
written informed consent for the collection and use of clinical samples. The study was approved 
by the Stockholm Regional Ethics Committee and conducted according to the Declaration of 
Helsinki Principles. 
 
 
Fig 6. Schematic diagram of biopsy collection from chronic non-healing wound-edges (A) and from 
healthy volunteers (B). 
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Human ex vivo wound model 
   We collected human skin that was discarded from abdominal reduction surgeries. All the skin 
donors were provided informed consent for the study. The study was approved by the Stockholm 
Regional Ethics Committee and conducted according to the Declaration of Helsinki Principles. A 
superficial wound was created using a 2-mm biopsy punch on the skin, then the wound was 
excised using a 6-mm biopsy punch, and subsequently transferred to a 12-well cell culture plate 
to let the tissue attach to the plate. Next, Dulbecco’s Modified Eagle’s Medium (DMEM) plus 10% 
fetal bovine serum (FBS) and antibiotics (penicillin 100 units/L and streptomycin 100 µg/ml; 
ThermoFisher Scientific, Carlsbad, CA) were added around the skin tissue, and let its epidermal 
surface exposed in the air to create a liquid-air interface (Fig 7). We topically treated the wounds 
with 0.1 nmol mirVana hsa-miR-132-3p mimic or miRNA negative control (ThermoFisher 
Scientific) packed in transfection reagent MaxSuppressorTM In Vivo RNA-LANCEr II (Bioo 
Scientific, Austin, TX) and then dissolved in 30% pluronic F- 127 gel (Sigma-Aldrich, St Louis, 
MO). Wound samples were collected 3 and 5 days after injury for gene expression and 
histological analysis.  
 
Fig 7. Schematic diagram of human ex vivo wound model. 
 
Mouse in vivo wound model 
   Male wildtype C57BL/6N mice (WT mice) and diabetic BKS(D)-Leprdb/JOrlRj mice (db/db mice) 
on the C57Bl/6J background were obtained from Janvier Labs (Le Genest-Saint-Isle, France). 
Mice were caged individually for one week, handled daily, before experiments. The hair on the 
back was shaved with an electric clipper followed by a depilatory cream and then washed with 
phosphate-buffered saline (PBS, 1X) one day before wounding. General anaesthesia was 
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performed with 3% isoflurane (Abbott, Chicago, IL, USA) and two full-thickness wounds were 
made on the dorsum using a 4-mm biopsy punch. Indicated dose of miRNA mimics or negative 
control (ThermoFisher Scientific) were mixed with MaxSuppressor™ In Vivo RNA-LANCEr II 
(Bioo Scientific) according to manufacturer's instruction in a total volume of 100μl for each 
wound. The mixtures were injected intradermally into the wound-edges of mice immediately after 
wounding. After the surgical procedure, mice received intraperitoneal buprenorphine (0.03 
mg/kg) for relief of possible pain and distress. The size of wound area was photographed every 
other day until euthanized. The wound area was measured using ImageJ 1.32 software (National 
Institutes of Health) and expressed as percentage of the original wound size. The mice were 
sacrificed at the specified time points after injury, and wound-edge tissues, intact skin and 
internal organs were collected for histology, gene expression and protein analysis. 
 
Laser capture microdissection (LCM) 
   Human skin or wound tissues were embedded in Tissue-Tek (Thermo Scientific) and snap-
frozen; mice tissues were fixed with formalin and then embedded in paraffin. Tissues were 
sectioned in 10-μm thickness and stained with hematoxylin. Laser capture microdissection was 
performed with Leica LMD7000 (Leica, Bernried, Germany). RNA from microdissected tissue 
was purified using miRNAeasy mini kit or miRNAeasy FFPE kit (Qiagen, Hilde, Germany). 
 
Magnetic-activated cell sorting (MACS) 
   Fresh human skin or wound samples were washed with cold PBS (1X) for 2–3 times and then 
incubated in 5 U/mL dispase (ThermoFisher Scientific) overnight at 4°C. Epidermis was 
separated from dermis using forceps. Epidermis was diced using scissors and then digested in 
Trypsin/EDTA Solution (ThermoFisher Scientific) for 15 minutes at 37°C. From the epidermal 
cell suspension, CD45- and CD45+ cells were separated using CD45 microbeads with MACS 
MS magnetic columns (Miltenyi Biotec, Bergisch Gladbach, Germany). Dermis was incubated in 
the enzyme mix from the whole skin dissociation kit (Miltenyi Biotec) for 3 hours and further 
processed by Medicon tissue disruptor (BD Biosciences, San Diego, CA). Dermal cell 
suspension was sorted sequentially through CD90, CD14 and CD3 microbeads with MACS MS 
magnetic columns according to manufacturer’s instructions (Miltenyi Biotec).  
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Cell culture, transfections and treatments 
   Human dermal fibroblasts (HDFs) were isolated from adult human skin obtained from 
abdominal reduction plastic surgery. Briefly, after dispase digestion, dermis was cut into small 
pieces and washed with PBS (1X). After dermal tissue attached to cell culture plate of 12-well 
plate, DMEM medium supplemented with 10% FBS and 1% penicillin streptomycin (100 units/mL 
Penicillin and 100 µg/mL Streptomycin, ThermoFisher Scientific) was added into the plate. After 
sufficient fibroblasts grew out from the dermal tissue which usually takes a week, the dermis 
pieces were removed and the cells were cultured to be confluent. The third to tenth passages of 
HDFs were used in this study. 
   Human adult epidermal keratinocytes (HEKa) were purchased from Cascade Biologics and 
cultured in EpiLife serum-free keratinocyte growth medium supplemented with Human 
Keratinocyte Growth Supplement at a final Ca2+ concentration of 0.06 mM and with penicillin 
streptomycin (ThermoFisher Scientific) at 37°C in 5% CO2. The fourth-passage of keratinocytes 
were used in this study.  
   HDFs or HEKa at 60% confluence were transfected with 20 nM mimics of a specific miRNA or 
miRNA negative control (ThermoFisher Scientific); 20 or 40 nM miRNA miRCURY LNA Power 
inhibitor or negative control A (Exiqon, Hilde, Germany); 20 or 30 nM Silencer select predesigned 
siRNA for specific gene or siRNA negative control (ThermoFisher Scientific) for 24 or 48 hours 
using LipofectamineTM 2000 (Invitrogen, Carlsbad, CA).  
   In some experiments, cells were treated with TGF-β1, TGF-β2 (10 ng/mL, Immuno tools), 
SB431542 (15 μM, Tocris), rh-TNF-α (50 ng/mL, R&D Systems, Minneapolis, MN), or Calycuin 
A (50 nM, Cell signalling).  
 
RNA extraction 
   Skin and wound biopsies from human or mice were homogenized in liquid nitrogen using a 
Mikro-Dismembrator U (B. Braun Biotech Inc.) or using Tissue Lyser LT (Qiagen) prior to RNA 
extraction. Total RNA was extracted from tissues using the miRNeasy Mini kit (Qiagen) and from 
cells using Trizol Reagent (ThermoFisher Scientific). RNA quantity and quality were determined 
using Nanodrop 2000 or Nanodrop one (ThermoFisher Scientific) and Agilent2200 Bioanalyzer 
chip (Agilent Technologies, Stockholm Sweden). 
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Transcriptomic profiling and analysis  
   Gene expression profiling of human or mice samples were performed using Affymetrix human 
HuGene-2_1-st, Clariom™ S or mouse Clariom™ D assays (ThermoFisher Scientific) at the 
microarray core facility of Karolinska Institute. Gene ontology analysis was performed according 
to the Database for Annotation, Visualization and Integrated Discovery (DAVID v6.8) (Huang da 
et al., 2009a, 2009b). Gene set enrichment analysis (GSEA) was performed using public 
software from Broad Institute (Mootha et al., 2003, Subramanian et al., 2005). The data have 
been deposited in the National Center for Biotechnology Information’s Gene Expression 
Omnibus and are accessible through GEO Series accession number (Edgar et al., 2002). 
 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
   Total RNA was reverse transcribed using specific miRNA reverse transcription (RT) primers or 
miRNA RT primer pool with MicroRNA Reverse Transcription Kit (ThermoFisher Scientific) for 
miRNA detection, or using RevertAid First Strand cDNA Sythesis Kit (ThermoFisher Scientific) 
for mRNA detection. Expression of miR-132, miR-31, miR-34a-5p and miR-34c-5p was 
determined by Taqman miRNA assays and normalized to RNU48 in human and U6 in mice. 
Expression of primary precursors of miR-132 or miR-31, RASA1, MKI67, EMP1, TNF, IL1B, IL8, 
CXCL1, CXCL5, CCL2, CCL20, LGR4, Tnf, Il1a, Il1b, Il6, Cxcl1, Cxcl5, Cxcl10, Ccl2 and Lgr4 
was detected by TaqMan based pre-designed qPCR assays (ThermoFisher Scientific or 
Integrated DNA Technologies, Coralville, IA). Gene expression was normalized based on the 
values of 18S rRNA or GAPDH in humans, and Gapdh or Actb in mice. Gene expression was 
detected by QuantStudioTM 7 Flex Real-Time PCR System (ThermoFisher Scientific), and 
relative expression was calculated using ΔΔCt. 
 
Histology, immunohistochemistry (IHC), and immunofluorescence (IF) staining 
   Tissues were paraffin-embedded and sectioned in 6μm thickness by microtome. After 
deparaffinization and rehydration, hematoxylin and eosin (H&E) staining were performed. The 
length and area of newly-formed epithelial tongue in wounds were quantified using Image J 
(National Institutes of Health).  
   IHC were performed to detect Gr-1 (1:100, BD Biosciences), Krt5 (1:2000, BioLegend, San 
Diego, CA), LGR4 (1:200, Sigma), CD45 (1:200, Abcam) and PCNA (1:20000, Abcam), which 
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were detected using specific first antibodies and the horseradish peroxidase (HRP)-conjugated 
secondary antibodies (DakoCytomation, Glostrup, Denmark). Second antibodies were 
visualized using VectaStain ABC Kit and AEC or DAB Peroxidase Substrate Kit (Vector 
Laboratories, Burlingame, CA).  
   IF were performed to detect Ki-67 (1:400, Cell Signaling Technology), α-SMA (1:200, Abcam, 
Cambridge, UK) and EMP1 (1:400, Abcam). Primary antibodies were detected with Alexa Fluor 
564-conjugated goat anti-rabbit IgG (H+L) (ThermoFisher Scientific) and visualized with a 
fluorescence microscope (Zeiss, Goettingen, Germany). DAPI (4’,6-diamidino-2-phenylindole, 
ThermoFisher Scientific) was used for nuclear staining. 
   Matched IgG isotype controls were included as negative control for each staining. All slides 
were evaluated by at least two independent observers unaware of the identity of the samples, 
and multiple sections were evaluated for each sample. 
 
In situ hybridization (ISH) 
   ISH was performed on formalin-fixed paraffin-embedded sections. Briefly, after 
deparaffinization, sections were treated with proteinase K (2 µg/mL) for 5 minutes at 37 °C and 
prehybridized for 30 minutes at 50/ 49°C for miR-132/ miR-31 respectively. Hybridization was 
performed for 2 hours at 50/ 49°C with a miR-specific or scramble digoxigenin (DIG)-labeled 
miRCURY locked nucleic acid probe (25nM) (Exiqon, Vedbaek, Denmark). Next, the slides were 
washed with 2X Saline-Sodium Citrate buffer (SSC) followed by incubation at 55/ 67°C (for miR-
132/miR-31 respectively) with 0.1X SCC buffer. The sections were incubated with alkaline 
phosphatase (AP) - conjugated sheep anti-DIG Fab fragments (1:1000, Roche, Mannheim, 
Germany) for one hour at room temperature. The probe was visualized by adding BM purple AP 
substrate according to the manufacturer’s instructions (Roche).  
 
Protein detection 
   Cell lysates prepared with radioimmunoprecipitation assay (RIPA) buffer (ThermoFisher 
Scientific) were resolved on 4-20% gradient gels and transferred onto nitrocellulose membrane 
(Bio-Rad). Western blotting was performed for EMP1 (1:1000, Abcam), LGR4 (1:500, Santa 
Cruz Biotechnology, Dallas, Texas), p-p65 Ser468 (1:1000, Cell Signaling Technology, Danvers, 
MA), p-p65 Ser536 (1:1000, Cell Signaling Technology), p65 (1:1000, Cell Signaling 
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Technology), p-GSK-3β (1:1000, Cell Signaling Technology), GSK-3 (1:5000, BD Transduction 
Laboratories) and β-actin (1:20000, Sigma). Immune complexes were detected by AmershamTM 
ECLTM Prime Western Blotting Detection Reagent according to the manufacturer’s protocol (GE 
Healthcare, Buckinghamshire, UK). 
   Conditioned medium from cultured keratinocytes was collected, and protein levels of IL-8 and 
CXCL5 were measured by enzyme-linked immunosorbent assay (ELISA) (BioLegend, San 
Diego, CA) according to the manufacturer’s instructions. 
 
Neutrophil chemotaxis assay 
   Whole blood was collected by venipuncture from healthy volunteers in 0.2% EDTA-
anticoagulated tubes. Erythrocytes were removed using dextran sedimentation (1:1 mixture of 
blood with 6% dextran/0.9% NaCl) followed by hypotonic lysis using ddH2O. Neutrophils were 
isolated from the resulting cell suspension using Ficoll-Histopaque (Sigma, St. Louis, MO) 
density centrifugation. Purified neutrophils were suspended in EpiLife medium. Using a 3μm 
polyethylene terephthalate membrane cell culture insert (BD Biosciences), 3x105 neutrophils 
were added to the inner chamber, while the outer chamber contained conditioned medium from 
treated or control keratinocytes. After incubation for 1.5 hours at 37 °C in 5% CO2, the migrated 
neutrophils in the outer chamber were counted using CountBrightTM absolute counting beads 
(ThermoFisher Scientific) in a FACScan flow cytometer (Beckman Coulter CyAn ADP). 
 
Analysis of cell growth 
   CyQUANT® Cell Proliferation Assay was performed according to the manufacturer’s 
instructions (Invitrogen, Karlsruhe, Germany).  
   EdU (5-ethynyl-2'-deoxyuridine) cell cycle assay was performed using Click-ItTM EdU Imaging 
Kit (ThermoFisher Scientific) performed according to the manufacturer’s instructions and 
analyzed on a FACScan flow cytometer (Beckman Coulter CyAn ADP). 
   For colony formation assays, HEKa were seeded into 12-well plate (8000 cells/well) 24 hours 
after transfection. After 7-10 days, the cells were stained with 0.1% crystal violet (Sigma-Aldrich, 
Saint Louis, MO) and photographed. Methanol was used to dissolve crystal violet and 
absorbance value was measured at 540 nm. 
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Analysis of cell migration 
   For scratch assay, when transfected HDFs were grown to full confluence in collagen-coated 
6-well plate, a scratch was made manually with a 10 μL pipette tip. The cells were incubated with 
DMEM medium supplemented with mitomycin C (10 μg/mL, Sigma-Aldrich) and photographed 
under microscope at the indicated time points. The wound areas were measured using Image J 
(National Institutes of Health). Healing rate = 100% - percentage of the initial wound area size. 
We also evaluate cell migration using IncuCyte® live cell analysis system. Transfected HEKa 
were grown to full confluence in ImageLock 96-well plate (Essen BioScience, Ann Arbor, MI) and 
scratch wound was made using an Essen® 96-pin WoundMaker™ (Essen BioScience). The 
assay plates were incubated in the IncuCyte® live cell analysis system (Essen BioScience), and 
the IncuCyte® ZOOM software was set to scan the plates every 2 hours and analyze cell 
migration. 
   Transwell migration assay was performed using the Corning® Matrigel® Chamber 8 µm (BD 
Falcon). 1x105 transfected cells in growth-factor-free medium were placed into the inner chamber 
of the insert. Medium containing growth factor was added into the outer chamber. 24 hours later, 
the cells migrated through the membrane were stained with 0.1% crystal violet and counted 
under microscope. 
 
Luciferase reporter assay 
   Luciferase reporter plasmids (SwitchGear Genomics, Menlo Park, CA.) were designed to 
contain either wildtype 3’-UTR of predicted miRNA target gene or mutation of the predicted target 
sites. HEKa were co-transfected with 0.1 µg of the luciferase reporter plasmids with 2 pmol 
miRNA or control mimics using LipofectamineTM 2000 in a 96-well plate. Luciferase assays were 
performed 48 hours after transfection using the dual-luciferase reporter assay system (Promega, 
Madison, WI, USA). 
 
Statistics 
   Statistical significance was determined by two tailed Student’s t-test or Wilcoxon Matched Pairs 
Signed Rank Test or Mann-Whitney U Test. Differences between groups were computed using 
two-way repeated-measures ANOVA. The correlation between the expressions of different 
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genes in the same sample was made using Pearson’s correlation test. For all statistical tests, P 
values < 0.05 were considered to be statistically significant. 
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4 RESULTS AND DISCUSSION 
 
4.1 MICRORNA-31 PROMOTES RE-EPITHELIALIZATION BY 
TARGETING EMP1 
We have performed a miRNA profiling and identified miR-31 as one of the top upregulated 
miRNAs in the human wounds at the inflammatory phase compared to the intact skin (Li et al., 
2015). Interestingly, increased miR-31 expression has also been found in psoriasis (Morhenn et 
al., 2013, Xu et al., 2013) and in cutaneous squamous cell carcinoma (Bruegger et al., 2013b, 
Wang A. et al., 2014), both of which are skin diseases with keratinocyte hyper-proliferation. 
Moreover, miR-31 has been reported to regulate keratinocyte differentiation (Peng et al., 2012) 
and hair growth (Mardaryev et al., 2010). In this study, we aimed to understand the role of miR-
31 in human skin wound healing. 
 
4.1.1 MiR-31 expression is up-regulated in wound-edge keratinocytes 
In human in vivo skin wound model (Fig 6B), we found that the levels of both primary 
transcript and mature form of miR-31 were gradually increased with wound healing, which was 
shown by qRT-PCR analysis (Fig 8 A-B; Paper I, Fig 1a-c). Moreover, we separated epidermal 
and dermal compartments of the skin and wound-edges using LCM, and we found that miR-31 
was majorly up-regulated in the epidermal keratinocytes during wound repair (Fig 8C), which 
was further confirmed by miR-31 in situ hybridization assay (Fig 8D; Paper I, Fig 1d-e). 
Therefore, in the following study, we focused on the role of miR-31 in keratinocytes. 
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Fig 8. The expression of mature (A) and primary transcript of miR-31 (B) in human wound biopsies 
detected by qRT-PCR. (C) MiR-31 expression in the epidermis and dermis of human wounds 
separated by LCM. (D) In situ hybridization of miR-31 in human skin (Day 0) and wounds (Day 1 and 
Day 7 after injury). Reproduced with permission from Li et al., 2015. Copyright The Society of 
Investigative Dermatology and Elsevier. 
 
4.1.2 MiR-31 promotes keratinocyte proliferation and migration 
Either double-stranded miR-31 mimics (pre-miR-31) or miR-31 specific inhibitors (anti-miR-
31) were transfected to human primary keratinocytes to overexpress or knock-down miR-31 
respectively. To study the impact of miR-31 on keratinocyte growth, we analysed the transfected 
keratinocytes with CyQUANT cell proliferation assay (Fig 9A; Paper I, Fig 2a), detection of 
proliferation marker Ki-67 expression (Fig 9B; Paper I, Fig 2b), colony formation assay (Fig 9C; 
Paper I, Fig 2d-e) and EdU cell cycle assay (Fig 9D; Paper I, Fig 2c). And we found that miR-31 
promoted proliferation and long-term growth of keratinocytes. Moreover, we performed scratch 
wound healing assay (Fig 9E-F; Paper I, Fig 3a-b) and transwell migration assay (Fig 9G-H; 
Paper I, Fig 3c-d), both showing that miR-31 enhanced keratinocyte motility.  
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Fig 9. In HEKa transfected with miR-31mimics (pre-miR-31) or inhibitors (anti-miR-31), the following 
assays were performed: (A) CyQUANT cell proliferation assay. (B) Expression of proliferation marker 
Ki-67 detected by qRT-PCR. (C) Quantification of colony formation assay. (D) EdU cell cycle assay. 
(E-F) Scratch assay. (G-H) Transwell migration assay. Reproduced with permission from Li et al., 
2015. Copyright The Society of Investigative Dermatology and Elsevier. 
 
4.1.3 EMP1 is an important target of miR-31  
Epithelial membrane protein 1 (EMP1) was previously identified as a direct target of miR-31 
in oesophageal squamous cell carcinoma (Zhang et al., 2011), and here we confirmed this 
finding in HEKa using 3’UTR luciferase reporter assay (Fig 10A; Paper I, Fig 4a-c). Moreover, 
we showed that the expression of EMP1 was negatively correlated with the level of miR-31 in 
human keratinocytes (Fig 10B; Paper I, Fig 4d-e) and also during skin wound healing (Fig 10C-
D; Paper I, Fig 4f-h). Furthermore, we found that silencing of EMP1 mimicked the effects of miR-
31 overexpression in keratinocytes, i.e. enhancement of cell proliferation and migration (Fig 10E-
G; Paper I, Fig 5), implying that EMP1 is a critical target mediating the functions of miR-31 in 
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keratinocytes. TGF-β1 was previously identified as an inducer of miR-31 expression in 
keratinocytes by our group (Xu et al., 2013), and here we discovered that TGF-β2 also induced 
miR-31 expression, repressing EMP1 expression (Paper I, Fig 6a-g). 
 
Fig 10. (A)  Luciferase reporter plasmids containing wild-type (WT) or mutant (Mut) 3’-UTR of EMP1 
were transfected into HEKa together with pre-miR-31 or control, and luciferase activity was 
measured. (B) Expression of EMP1 mRNA in keratinocytes overexpressing or lacking miR-31. (C) 
Expression of EMP1 mRNA in human wounds detected by qRT-PCR. (D) Spearman-correlation of 
EMP1 with miR-31 expression in human wounds. QRT-PCR of proliferation marker Ki-67 (E), colony 
formation assay (F), and scratch migration assay (G) were performed in HEKa with EMP1 expression 
silencing. (H) Schematic summary of the results in section 4.1. Reproduced with permission from Li 
et al., 2015. Copyright The Society of Investigative Dermatology and Elsevier. 
 
4.1.4 Discussion 
   In this study, we characterized the dynamic expression pattern of miR-31 during normal human 
skin wound healing process. The basal level of miR-31 is low in the intact skin, while upon injury 
its expression gradually increases from day 1 (inflammatory phase) through day 7 (proliferative 
phase). Comparing this with its primary transcript (pri-miR-31), which is only upregulated in day-
7 wounds, we assume that the change of miR-31 level during wound healing results from 
different regulatory mechanisms: the early increase of mature miR-31 is likely due to faster 
processing of the existing pri-miR-31, yet its later and stronger upregulation requires enhanced 
transcription of miR-31 gene.  
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   To understand how the increased miR-31 expression affects skin wound healing, we 
performed different functional assays in human primary keratinocytes with miR-31 
overexpression or inhibition. Our results reveal that miR-31 promotes both the proliferation and 
migration of keratinocytes, which are fundamental cellular events during the proliferative phase. 
Thereby, the high expression of miR-31 in keratinocytes in the proliferative phase may be 
important for the re-epithelialization process. 
   In addition to our findings, miR-31 has been known as an important regulator in other 
physiological processes of the skin, i.e., miR-31 regulates epidermal keratinocyte differentiation 
by enhancing Notch signalling (Peng et al., 2012); and miR-31 is upregulated in the anagen 
phase of hair cycle, while inhibition of miR-31 accelerates anagen development (Mardaryev et 
al., 2010). Moreover, miR-31 expression has also been found upregulated in several skin 
diseases, such as in psoriasis miR-31 promotes cytokine and chemokine production of 
keratinocytes (Morhenn et al., 2013, Xu et al., 2013); while in cutaneous squamous cell 
carcinoma miR-31 facilitates the motility and colony-forming ability of cancer cells (Bruegger et 
al., 2013a, Wang A. et al., 2014). Taken together, miR-31 is an important regulator in epidermal 
keratinocytes under both physiological and pathological conditions.  
   To understand the underlying molecular mechanism of miR-31-mediated regulation, we aimed 
to identify its direct targets. By combining bioinformatic and experimental strategies, here we 
demonstrate that EMP1 is targeted by miR-31 in keratinocytes. EMP1 has been mainly 
recognized as a tumour suppressor previously, as it inhibits growth and motility of different types 
of cancer cells (Sun G. et al., 2014, Sun G. G. et al., 2014a, Sun G. G. et al., 2014b, Sun G. G. 
et al., 2014c, Zhang et al., 2011). Here we show that EMP1 also suppresses growth and 
migration of normal human keratinocytes. In the wound-edge tissues from the inflammatory to 
the proliferative phases, we observed a negative-correlated expression pattern between miR-31 
and EMP1, implying that miR-31 may down-regulate EMP1 expression in human wounds in vivo. 
However, the expression of both miR-31 and EMP1 is activated in day-1 wound compared to the 
intact skin, indicating that EMP1 expression is induced by other unknown factors at the early 
phase of skin wound healing, which warrants further investigation.  
In conclusion, our study proposes that during normal skin wound healing, the increase of 
miR-31 level by TGF-β1 and TGF-β2 enhances proliferation and migration of keratinocytes, and 
miR-31 exerts these functions partially by targeting EMP1, which collectively facilitate re-
epithelialization (Fig H; Paper I, Fig 6h). Our result is confirmed by a recent report using miR-31 
loss-of-function mouse models (Shi et al., 2018), demonstrating miR-31 as an important 
molecule regulating keratinocyte function to improve wound healing.  
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4.2 MICRORNA-34 FAMILY ENHANCES WOUND INFLAMMATION BY 
TARGETING LGR4 
As a major cell type in epidermis, keratinocyte is not only indispensable for re-
epithelialization, but also important in the immune response of the skin.  When skin gets hurt, 
keratinocytes are the first to capture signals of physical trauma or other external stimuli, and start 
innate immune response by producing cytokines and chemokines (Chen and DiPietro, 2017, 
Strbo et al., 2014). The chronic non-healing wound has been characterized by excessive and 
prolonged inflammation, which impedes wound healing and causes additional tissue damage. 
However, largely still awaits to be explored about the role of keratinocytes in the chronic 
inflammation.  
   MicroRNA-34 family has been well known for their tumour suppressive functions, especially 
inhibition of cancer cell mitosis and migration. Moreover, miR-34a is the first microRNA entering 
clinical trial (ClinicalTrials.gov Identifier: NCT01829971 and NCT02862145) (Beg et al., 2017). 
Tumour and wound healing share various similar mechanisms (Sundaram et al., 2018), thus 
miR-34 raised our interest.  
 
4.2.1 Increased miR-34a and miR-34c expression in the wound-edge 
keratinocytes of human venous ulcers 
Our recent RNA-sequencing study identified miR-34a and miR-34c among the top up-
regulated miRNAs in VUs compared with normal wounds (NW) or intact skin from healthy donors 
(unpublished data). MiRNA-34 family comprises three homologues, miR-34a, b and c, but only 
miR-34a-5p and miR-34c-5p, but not miR-34b, are detected in human skin and wound tissues 
by RNA-sequencing analysis (Paper II, Fig. S1). For validation, 19 VU samples were collected 
and compared with normal wounds or skin tissues from 7 healthy volunteers (Fig 11A; Paper II, 
Table 1). Both miR-34a and miR-34c were validated higher expressed in VU compared with 
either normal wounds or intact skin by qRT-PCR (Fig 11B-C; Paper II, Fig 1A-B). Besides, in the 
LCM isolated wound-edge epidermis, which are mainly composed of keratinocytes, more miR-
34 expression was detected in the VUs than the skin or normal wounds (Fig 11D-F; Paper II, Fig 
1C-E).  
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Fig 11. (A) Characteristics of healthy donors and VU patients. QRT-PCR analysis of miR-34a (B) and 
miR-34c (C) in the skin and wound biopsies. (D-F) QRT-PCR analysis of miR-34 expression in LCM 
separated epidermis. 
 
4.2.2 MiR-34 enhances keratinocyte inflammatory response and impedes 
wound healing  
Transcriptomic analysis of HEKa overexpressing miR-34a or miR-34c suggests that these 
miRNAs not only play a role in cell proliferation, but also in innate immune response and 
inflammation (Paper II, Fig 2). We show that in human primary keratinocytes, miR-34a and miR-
34c promoted the production of several cytokines and chemokines, for instance TNF and CXCL5 
(Fig 12A; Paper II, Fig 3A-B). 
   In wild-type mice (Fig 12B; Paper II, Fig 4A), liposome-encapsulated miR-34a mimics were 
intradermally injected around the wounds once after injury, which led to a transient 
overexpression of miR-34a (Fig 12C; Paper II, Fig 4B). Interestingly, local overexpression of 
miR-34a delayed wound closure macroscopically (Fig 12D, F; Paper II, Fig 4C-D) and impaired 
formation of new epidermal tongue microscopically (Fig 12E, G; Paper II, Fig 4E-F). Elevated 
cytokine and chemokine expression was observed in miR-34-treated wounds, indicating 
enhanced local inflammation (Fig 12I; Paper II, Fig 4G).   
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Fig 12. (A) QRT-PCR analysis of TNF and in HEKa overexpressing miR-34. (B) Experimental setup 
of mouse in vivo wound model. (C) QRT-PCR of miR-34a in treated mice wounds. (D) Quantification 
of wound closure. (E) Measurement of the length of the newly-formed epithelial tongue. (F) 
Representative pictures of mice wounds. (G) Representative pictures of H&E stained wound tissues. 
(H) QRT-PCR analysis of Tnf and Cxcl5 in mice wounds.  
 
4.2.3 LGR4 is a target mediating the biological function of miR-34 in 
keratinocytes  
Combining eleven different miRNA target algorithms and microarray of HEKa overexpressing 
miR-34a or miR-34c, five genes were commonly predicted as targets of miR-34. After checking 
the expression of these five genes in human skin and wound samples, we found that the level 
of LGR4 was negatively correlated with miR-34 expression in vivo (Fig 13A; Paper II, Fig 5A-C, 
Fig S5), suggesting that LGR4 may be a miR-34 target in human skin wounds. This was 
experimentally verified by 3’UTR luciferase reporter assay in human primary keratinocytes (Fig 
13B; Paper II, Fig 5D-E, I). Accordingly, we showed that overexpression of miR-34 supressed 
LGR4 expression (Fig 13C; Paper II, Fig 5F-H).  
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Silencing of LGR4 in human keratinocytes results in increased IL-8 and CXCL5 production, 
which phenocopied the pro-inflammatory function of miR-34a and miR-34c (Fig 13D; Paper II, 
Fig 6A-E). Furthermore, while miR-34 inhibitor reduces cytokine and chemokines production, 
additional silencing of LGR4 could rescue this anti-inflammatory effect (Paper II, Fig 6F), 
indicating that miR-34a/c exert their pro-inflammatory function through targeting LGR4. 
Interestingly, we found that wound closure is slower in Lgr4 knock-out mice compared with wild-
type mice (Fig 13E-F; Paper II, Fig 7A-C). Inflammatory molecular signature (such as increased 
tnf and Cxcl5 expression) and more infiltrated immune cells (Fig 13G-H; Paper II, Fig 7E-F) were 
detected in the wounds of Lgr4 KO mice compared with WT mice, which is similar as the mice 
wounds with miR-34a overexpression (Paper II, Fig 4). 
Mechanistically, previous studies have reported that LGR4 inhibits GSK-3β serine 9 (Ser9) 
phosphorylation, thus increasing the proportion of the unphosphorylated active GSK-3β (Luo et 
al., 2016, Zhang et al., 2003); and GSK-3β phosphorylats p65 at Ser468, which negatively 
regulates NF-κB activity (Buss et al., 2004). And our findings link these two pieces of evidences, 
showing that miR-34-LGR4 axis regulates GSK-3β-induced p65 Ser468 phosphorylation, thus 
impacting the activity of NF-κB signal that is a central signalling pathway controlling cellular 
inflammatory response (Fig 13I; Paper II, Fig 8). 
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Fig 13. (A) The expression of LGR4 in VUs was detected by qRT-PCR. (B) Luciferase assay in human 
keratinocytes co-transfected wild-type or mutant LGR4 3’UTR luciferase reporters with miR-34 
mimics. (C) Western blotting analysis of LGR4 in keratinocytes overexpressing miR-34. (D) QRT-
PCR of IL8 and CXCL5 in HEKa with LGR4 silencing. (E) Representative pictures of WT and Lgr4 
KO mice wounds. (F) Wound healing rate of WT or Lgr4 KO mice. (G) MRNA expression of Tnf and 
Cxcl5 in WT and Lgr4 KO mice wounds. (H) Quantification of immunohistochemistry staining of 
CD45+ immune cells in mice wounds. (I) Schematic summary of the results in section 4.2. 
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4.2.4 Discussion 
   MiR-34 family members are well-known tumour suppressor in a wide range of cancer types 
(Wang et al., 2015, Wong et al., 2011). Several in vitro studies have shown that overexpression 
of miR-34a reduces cell proliferation, migration, invasion, stemness while increasing apoptosis 
and senescence in various cancer cell lines (Bader, 2012, Maroof et al., 2014). In various animal 
models, treatment with miR-34a mimics have been shown to inhibit the growth of primary 
tumours, block metastasis, and improve survival (Adams et al., 2016, Bader, 2012, Moles, 2017). 
Nonetheless, a clinical trial of miR-34 treatment in cancer patients has been terminated recently, 
because of severe immune-related adverse events (Beg et al., 2017), which exposes an urgent 
need to understand the role of miR-34 in immune response. To this end, miR-34a has been 
shown to inhibit B cell development (Rao et al., 2010), facilitate dendritic cell differentiation 
(Hashimi et al., 2009), inhibit macrophages efferocytosis (McCubbrey et al., 2016), impair 
neutrophils migration but enhance their production of TNF (Cao et al., 2015, Shikama et al., 
2016).  Our study reveals that miR-34a and miR34c also increase the production of pro-
inflammatory cytokines and chemokines from epidermal keratinocytes, enhancing the capacity 
of keratinocytes to recruit and activate immune cells in skin wounds, which conforms to the 
excessive inflammation of VUs where miR-34 is overexpressed.   
   We identified LGR4 as a direct target of both miR-34a and miR-34c, which is a leucine-rich 
repeat-containing G-protein coupled receptor. It has been reported that LGR4 induces 
keratinocyte proliferation (Jin et al., 2008, Kato et al., 2007, Wang et al., 2010), and loss of LGR4 
results in partially impaired hair follicle development (Mohri et al., 2008). In addition, in 
macrophages LGR4 was reported to play an anti-inflammatory role (Du et al., 2013), and to 
enhance anti-inflammatory M2 polarization (Tan et al., 2018). Here we show that loss of LGR4 
enhances inflammatory response and impairs wound re-epithelization.  
    Our study identified miR-34a and miR-34c among the top up-regulated miRNAs in VU 
compared to intact skin or acute wounds from healthy donors, which function to exacerbate 
keratinocyte inflammatory response and delayed wound closure by targeting LGR4, implying 
their pathological role in chronic wounds. 
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4.3 MICRORNA-132 FACILITATES FIBROBLAST MIGRATION BY 
TARGETING RASA1 
In addition to epidermal keratinocytes, dermal fibroblasts also play an essential role in skin 
wound healing, such as to form granulation tissue, contract wound, regulate angiogenesis, assist 
re-epithelialization, produce extracellular matrix and reconstruct new dermis. Primary fibroblasts 
derived from the non-healing edges of chronic wounds display impaired cellular functions, 
including reduced proliferative and migratory capacities, decreased secretion and response to 
various growth factors, and excessive production of proteinases.  
In our previous study (Li et al., 2015), microRNA-132 (miR-132) was identified as a top up-
regulated miRNA in the inflammatory phase of human acute wounds compared with the intact 
skin from the same donor. We show that miR-132 impedes inflammatory response but boosts 
cell proliferation in primary epidermal keratinocytes by directly targeting HB-EGF. Local inhibition 
of miR-132 delays wound closure in mouse in vivo and human ex vivo wound models (Li et al., 
2015). Following this research line, we further investigated the function of miR-132 in human 
dermal fibroblasts (HDFs). 
  
4.3.1 The expression pattern of miR-132 during human normal skin wound 
healing 
To reveal the expression pattern of miR-132 during human skin wound healing, we collected 
intact skin and acute wounds at the inflammatory phase (1 day after injury) and at the proliferative 
phase (7 days after wounding) from healthy volunteers (Fig 6; Paper III, Fig 1A). Using laser 
capture microdissection, we found that miR-132 expression was increased in both epidermal 
and dermal compartments of wound-edges compared to the intact skin (Fig 14A; Paper III, Fig 
1B). Next, using MACS magnetic cell separation, we isolated several cell types from the skin 
and wounds, i.e. epidermal CD45- cells (mainly keratinocytes) and CD45+ cells (leukocytes), 
dermal CD90+ cells (fibroblasts), CD14+ cells (macrophages), and CD3+ cells (T cells). 
Interestingly, miR-132 was found highly expressed in human dermal CD90+ HDFs (Fig 14B; 
Paper III, Fig 1C) and its level was upregulated by skin injury (Fig 14C; Paper III, Fig 1D). In 
addition, we found TGF-β1 increased miR-132 transcription in HDFs, which effect could be 
specifically blocked by TGF-β receptor inhibitor (Paper III, Fig 1E-G). 
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Fig 14. QRT-PCR of miR-132 in LCM separated human epidermis and dermis from human skin and 
wounds (A), in different cell populations isolated from human skin (B), in CD90+ cells isolated from 
the skin and acute wounds (C). Reproduced with permission from Li et al., 2017. Copyright Springer 
Nature Publishing AG. 
 
4.3.2 MiR-132 promotes HDF migration by targeting RASA1 
To reveal the role of miR-132 in dermal fibroblasts, microarray analysis was performed in 
HDFs transfected with miR-132 mimics. Gene ontology (GO) and gene set enrichment analysis 
(GSEA) analysis of microarray data suggested that miR-132 may have an impact on cell motility 
(Fig 15A-C; Paper III, Fig 2). Using both scratch wound healing assay (Fig 15D; Paper III, Fig 
3A) and transwell migration assay in HDF transfected miR-132 mimics or inhibitors, we 
demonstrated that miR-132 promoted fibroblast migration (Fig 15E; Paper III, Fig 3C). (Paper III, 
Fig 3 B, D),  
 56 
 
Fig. 15. (A) The top10 gene ontology of cell component terms for the genes down-regulated by miR-
132 in fibroblasts. GSEA evaluated enrichment within the microarray data for the genes reported to 
accelerate (B) or impair (C) cell migration. Scratch assays (D) and transwell migration assays (E) for 
HDFs transfected with miR-132 mimics. Reproduced with permission from Li et al., 2017. Copyright 
Springer Nature Publishing AG. 
 
In the transcriptomic analysis, we found that RAS signalling pathway was regulated by miR-
132 (Fig 16A; Paper III, Fig 4A-B). Among the RAS related genes, we noticed that RASA1 (RAS 
p21 protein activator 1) was one of the top down-regulated genes upon miR-132 overexpression 
(Paper III, Fig 4C). RASA1 has been previously reported as a direct target of miR-132 in 293T 
cells and mouse dorsal root ganglion neurons (Anand et al., 2010, Hancock et al., 2014), and 
here we found miR-132 also supressed RASA1 expression in HDFs (Fig 16B; Paper III, Fig 4C-
D), Moreover, silencing of RASA1 promotes HDF migration (Fig 16C-D; Paper III, Fig 5A-C), 
phenocopying miR-132 overexpression.  
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Fig 16. (A) GSEA for RAS-related genes within the microarray data. (B) Expression of RASA1 in 
HDFs overexpressing miR-132. Transwell migration assay (C) and scratch assay (D) for HDFs with 
RASA1 silencing. (E) Schematic summary of the results in section 4.3. Reproduced with permission 
from Li et al., 2017. Copyright Springer Nature Publishing AG. 
 
4.3.3 Discussion 
   Together with our previous study (Li et al., 2015), we show that miR-132 expression is up-
regulated in both wound-edge keratinocytes and dermal fibroblasts during normal skin wound 
healing (Fig 14; Paper III Fig 1A-D). During this study, we established MACS magnetic cell 
isolation protocol with limited quantity of human samples. Using this methodology, more detailed 
gene expression profiles could be studied in different cell populations from normal wound and 
chronic wound samples, which might be beneficial to identify key etiological factors and further 
to design treatment by correcting them.  
   Transcriptomic analysis of fibroblasts overexpressing miR-132 leads us to focus on the effect 
of miR-132 on cell migration. Using several functional assays, we demonstrate that miR-132 
enhances the motility of HDFs. Moreover, we find that RAS signalling is regulated by miR-132 
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in HDFs and among the genes involved in this signalling pathway RASA1 is a direct target of 
miR-132. RAS is a small GTPase switching between an active GTP-bound and an inactive GDP-
bound state, and RASA1 is one of the critical RAS GTPase activating proteins (RasGAP) which 
negatively regulates RAS activity by increasing the rate of GTP hydrolysis (Pamonsinlapatham 
et al., 2009, Rajalingam et al., 2007). Stimulated by tyrosine kinase or growth factor receptors, 
RAS gets activated and acts through its effectors, for instance RAF, PI3K, MEKK signalling 
cascades, thus controlling various basic cellular functions (Rajalingam et al., 2007). To our 
interest, RAS signalling has been shown to regulate the motility of fibroblasts and keratinocytes 
during skin wound healing (Ehrenreiter et al., 2005). Moreover, RASA1 interacts with p190 
RhoGAP to regulate directed movement of fibroblasts (Kulkarni et al., 2000). It also inhibits cell 
migration by competing with Rab21 to bind integrins and regulating receptor trafficking (Mai et 
al., 2011). In accordance with this, we show that silencing of RASA1 increases fibroblast 
migration, which phenocopies the effects of miR-132, suggesting that the RASA1-RAS signal 
axis is critical in mediating the pro-migratory effect of miR-132 in fibroblasts. 
   In addition, miR-132 has been found highly expressed and play functional roles in some other 
cell types involved in skin wound healing (Fig 14B-C; Paper III, Fig 1B-C). Besides keratinocytes, 
the anti-inflammatory effects of miR-132 has also been reported in monocytes and macrophages 
(Essandoh et al., 2016, Li et al., 2015, Liu et al., 2015, Nahid et al., 2013). Moreover, miR-132 
is up-regulated in neutrophils after their extravasation and infiltration into the skin (Larsen et al., 
2013). MiR-132 has also been shown to enhance endothelial cell proliferation and improve 
vascularization (Anand et al., 2010, Devalliere et al., 2014, Lei et al., 2015, Mulik et al., 2012, 
Westenskow et al., 2013).  Together with our findings showing that  miR-132 promotes HDF 
migration, we propose that miR-132 may be a promising candidate to be used in wound 
treatment, which idea was tested in the paper IV.   
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4.4 MICRORNA-132 IMPROVES WOUND HEALING OF DIABETIC 
MOUSE MODEL AND HUMAN EX VIVO MODEL 
Chronic wound is a growing health and economic problem worldwide. Diabetic foot ulcer 
(DFU) is the most difficult type of chronic wounds to treat, and it is associated with high 
amputation rate and mortality. Our previous studies revealed that in epidermal keratinocytes 
miR-132 has pro-proliferative and anti-inflammatory function (Li et al., 2015), and in dermal 
fibroblasts miR-132 plays a pro-migratory role (Paper III). Based on these findings, we further 
explored the therapeutic potential of miR-132 in chronic wounds, in particular DFU.  
 
4.4.1 The expression of miR-132 is decreased in human diabetic foot ulcers and 
in diabetic mouse wounds 
To study DFU, we have been collecting wound-edge biopsies of DFU from patients with type 
2 diabetes mellitus and also acute wounds and intact skin from healthy volunteers (Fig 17A-B; 
Paper IV, Fig 1a, Table 1). MiR-132 expression is found significantly reduced in the DFU, 
especially in the epidermal compartment, compared to the normal skin wounds, shown by qRT-
PCR (Fig 17C; Paper IV, Fig 1b) and in situ hybridization (Fig 17D; Paper IV, Fig 1c). Similarly, 
lower miR-132 expression was observed in wounds of leptin receptor-deficient (db/db) mice, 
which is a commonly used diabetic model, compared to the wild-type mice (Fig 17E; Paper IV, 
Fig 1d). 
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Fig 17. (A) Sample collection. (B) Characteristics of DFU patients. Analysis of miR-132 expression in 
human skin and wounds of healthy donors and DFUs by qRT-PCR (C) and in situ hybridization (D). 
(E) QRT-PCR of miR-132 in skin and wound of WT or db/db mice. Reproduced with permission from 
Li et al., 2017. Copyright The Society of Investigative Dermatology and Elsevier. 
 
4.4.2 MiR-132 promotes wound healing of diabetic mice 
Full-thickness wounds were made on the dorsum of db/db mice using a 4 mm biopsy punch 
(Fig 18A; Paper IV, Fig 2c), and then intradermal injection of miR-132 mimics around the wounds 
overexpressed miR-132 successfully (Fig 18B; Paper IV, Fig 2d-e). Local injection of miR-132 
mimics accelerated wound healing of db/db diabetic mice, which was assessed by both 
macroscopic (Fig 18C-D; Paper IV, Fig 3a-b) and histomorphometry analysis (Fig 18E-G; Paper 
IV, Fig 3c-e). MiR-132 overexpression increased wound-edge keratinocyte proliferation (Fig 
18H-I; Paper IV, Fig 3f-g) and reduced local Cxcl1 expression and neutrophil infiltration (Fig 18J-
L; Paper IV, Fig 3h-j).  
Transcriptomic analysis was performed in the mice wounds treated by either control or miR-
132 mimics, showing that the miR-132 may negatively regulates several central inflammatory 
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signalling pathways, for example NF-κB signalling, TNF signalling, NOD-like receptor signalling 
and Toll-like receptor signalling pathways (Paper IV, Fig 4).  
 
Fig 18. (A) Experimental setup. (B) Expression analysis of miR-132 in mouse wound and internal 
organs. (C) Representative pictures of wounds. (D) Wound closure is characterized as healing rate 
= 100% - the percentage of the initial wound area size (n = 12 wounds/ group). Quantification of the 
length (E) and area (F) of newly-formed epithelial tongue. Count of Ki-67 (G) and Gr-1 positive cells 
(H), detected by immunohistochemistry, in wound-edge epidermis. Reproduced with permission from 
Li et al., 2017. Copyright The Society of Investigative Dermatology and Elsevier. 
 
4.4.3 MiR-132 accelerates re-epithelialization of human ex vivo wounds 
We further tested the effect of topical application of miR-132 on re-epithelization of human 
ex vivo wound. Liposome-formulated miR-132 mimics were mixed with pluronic F-127 gel, which 
is a commonly used thermos-reversible vehicle gel, and then the mixture was topically applied 
on human ex vivo wounds right after wounding (Fig 19A; Paper IV, Fig 5a). Three days later, ex 
vivo wounds were confirmed for miR-132 overexpression (Fig 19B; Paper IV, Fig 5b). Five days 
after wounding, we found that the miR-132-treated wounds were completely re-epithelialized, 
but not the control-treated group (Fig 19C-D; Paper IV, Fig 5c-d). Increased number of Ki-67+ 
keratinocytes was observed in the wound-edge epidermis of the miR-132 treated wounds 
compared with the control group (Fig 19E; Paper IV, Fig 5e-f). 
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Fig 19. (A) Experimental setup. (B) QRT-PCR analysis of miR-132 in the treated ex vivo wounds. (C) 
Representative pictures of H&E stained wounds. (D) Re-epithelization is characterized as healing 
rate. (E) Count of Ki-67 positive cells, detected by immunohistochemistry, in wound-edge epidermis. 
Reproduced with permission from Li et al., 2017. Copyright The Society of Investigative Dermatology 
and Elsevier. 
 
4.4.4 Discussion 
   In this study, we found a lower miR-132 expression in wound-edges of DFU. As TGF-β 
positively regulates miR-132 expression (Li et al., 2015), we hypothesize that the reduced level 
of miR-132 in DFU may result from lack of TGF-β signalling there (Jude et al., 2002).  
   We have previously shown that lack of miR-132 delays wound closure in WT mice with 
increased local inflammation and decreased cell growth (Li et al., 2015). Here we show that local 
administration of miR-132 accelerates wound healing in diabetic mice with suppressed 
inflammatory response and improved re-epithelialization. Transcriptomic analysis of miR-132-
treated mice wounds (Paper IV Fig 4) reveals an anti-inflammatory molecular signature, 
confirming our previous results showing that miR-132 represses the activity of the NF-kB 
signalling (Li et al., 2015). As DFU is featured with prolonged and excessive inflammation, our 
findings suggest that miR-132 may be used to treat chronic wounds by repressing inflammation. 
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Contraction mainly contributes to the wound closure in rodents, but not in humans (Volk and 
Bohling, 2013). We have previously shown that miR-132 does not affect mouse dermal fibroblast 
contraction (Li et al., 2015). And here we found that there was no obvious difference of 
myofibroblast presence in the dermis between the miR-132 mimics-treated group and the control 
group (Paper IV Figure S6). In addition, we did not observe any obvious difference in hair cycle 
between the miR-132 and the control-treated groups (Paper IV Fig 3k). These data demonstrate 
that the accelerated wound healing in the miR-132-treated group is not due to the impacts of 
miR-132 on contraction or hair follicle cycling. 
   Dysregulation of microRNA exists in most human diseases, therefore modulation of their 
expression opens new gates to invent treatments. A few miRNAs have marched into clinical 
trials, e.g. miR-34 for solid tumours, miR-103/107 for diabetes, and miR-122 for Hepatitis C virus 
infection. Nevertheless, shortages and challenges remain, such as the instability of designed 
molecules, difficulty of localized delivery, lack of biocompatible vehicles and hard-to-predict 
adverse effects (Chakraborty et al., 2017, Rupaimoole and Slack, 2017). Wound healing is a 
good niche to test miRNA-based therapy owing to the obvious advantages of easy access of the 
application site for topical administration and possibility for phenotypic evaluation. After 
intradermal injection of miR-132, its increased expression was not observed in the inner organs 
(Fig 18B; Paper IV Fig 2d, S4), suggesting the local administration is specific. Besides, no 
changes were discovered in body weight, blood glucose, or morphology and histology of internal 
organs between the miR-132-treated group versus the control group (Paper IV Fig S3, S5), 
indicating low systemic toxicity. LCM of the injected mouse wounds reveals efficient 
overexpression of miR-132 in both epidermis and dermis (Paper IV Fig 2e), implying its effects 
in multiple cellular types within the wounds.  
   Together, we identify miR-132 as a downregulated miRNA in DFU and local treatment with 
miR-132 mimics promotes wound closure in diabetic mice and re-epithelization of human ex vivo 
wounds by regulating multiple inflammation-related signalling pathways.  
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5 CONCLUSION 
   Skin is an imperative physical and immunological barrier of our body. Any disruption in skin 
integrity needs to be amended properly and efficiently in order to avoid manifestation of 
secondary complications. Wound healing is a complicated biological process involving 
interaction between different cell types and biomolecules, in order to restore barrier properties of 
the skin. Often this cascade of well-coordinated healing events gets delayed leading to formation 
of chronic non-healing wounds. Hence, we found it interesting to explore the contribution of 
different epidermal, dermal and immune cells in the skin, towards its healing ability, and how it 
gets altered in chronic wounds, with the major focus on microRNA mediated interactions. We 
believe the knowledge in this direction still has many caveats that require better understanding 
of the pathophysiology in order to design effective treatments. 
   In this direction, we first studied the expression of miRNA in normal human skin wound healing 
process and in chronic non-healing wounds. Using miRNA profiling (Li et al., 2015), miR-31 and 
miR-132 were identified as top up-regulated miRNAs in the inflammatory phase of wound 
healing. The expression of miR-31 was mainly confined to epidermal keratinocytes and was 
found to reach maximum during the proliferation phase (Paper I). Whereas miR-132 was 
gradually up-regulated in the inflammatory and proliferative phases, especially in epidermal 
keratinocytes and dermal fibroblasts of wounds. Additionally, miR-132 was also widely 
expressed in other immune cells in both epidermis and dermis (Paper III). Furthermore, we found 
an obvious down-regulation of miR-132 expression in diabetic ulcers, the most difficult type of 
chronic wound to treat, compared with normal wounds from healthy donors (Paper IV). On the 
other hand, miR-34 family exhibited increased expression in the epidermis of venous ulcer, the 
most common type of chronic wound, compared with either acute wounds or the intact skin 
(Paper II).  
Secondly, we explored the functions of miRNAs during different phases and in different cell 
types of skin wound healing. In the inflammatory phase, miR-132 was previously shown to be 
anti-inflammatory but pro-proliferative regulator of keratinocytes by targeting HB-EGF and 
activating EGFR, ERK, and STAT3 signalling (Li et al., 2015). In the proliferation phase, miR-31 
was found to promote keratinocyte proliferation and migration by targeting EMP1, thereby to 
facilitate re-epithelialization (Paper I). And miR-132 improved the migratory ability of dermal 
fibroblasts via targeting RASA1 and regulating Ras signalling, which benefits granulation tissue 
formation (Paper III). Since chronic wounds are non-epithelialized, excessively inflamed and 
fibroblasts derived from chronic wounds are non-migratory, our study suggests that miR-31 and 
miR-132 have potential therapeutic importance for chronic wounds (Paper I, III). 
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Third, we aimed to understand how the dysregulation of microRNAs contributes to chronic 
wounds. MiR-34 family was identified among the top up-regulated non-coding RNAs in VU, 
which enhanced inflammatory response of epidermal keratinocytes via targeting LGR4 and 
raising the activity of NF-κB signalling (Paper IV), suggesting the dysregulation of miR-34 plays 
a pathological role in excessive inflammation of VU (Paper II). Similarly, we found the level of 
miR-132 was decreased in DFU (Paper IV), and lack of miR-132 impeded wound healing (Li et 
al., 2015). 
Lastly, we examined the therapeutic potential of miRNA in chronic wounds. Based on 
previous findings and availability of animal models, we chose to test miR-132 in diabetic wounds. 
Interestingly, local overexpression of miR-132 accelerated wound closure in diabetic mice, 
where inflammatory cells and molecular signatures were remarkably reduced (Paper IV). 
Moreover, ex vivo human model also demonstrated accelerated re-epithelialization upon miR-
132 topical application, indicating that local treatment of miR-132 may be further evaluated in a 
clinical trial as a potential treatment for chronic wounds (Paper IV). 
   Altogether, we have selected three top regulated genes from microRNA profiling of normal 
wounds from healthy volunteers and of chronic wounds from patients (data not shown in this 
thesis). Their functional significance and mechanistic insights have been explored in normal 
wound healing and chronic wounds: miR-31 has been studied in keratinocytes where we 
accented its importance for re-epithelialization of normal wound healing, miR-34 is one of the top 
upregulated microRNAs in venous ulcer with pro-inflammatory roles in keratinocytes and 
impaired mouse wound healing, and miR-132 has been explored in dermal fibroblasts with 
promising therapeutic potential in diabetic ulcers. In conclusion, this thesis highlights the crucial 
roles of miRNAs in keratinocytes and fibroblasts during skin wound healing, and demonstrates 
their dysregulation contributes to the pathogenesis of chronic wounds. Correction of these 
dysregulated miRNAs indicates a novel strategy to treat the chronic wounds such as diabetic 
ulcer and venous ulcer.  
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